WO2021155151A1 - Ligands multivalents ciblant des récepteurs de surface cellulaire et plateforme de mesure de force pour leur fabrication - Google Patents

Ligands multivalents ciblant des récepteurs de surface cellulaire et plateforme de mesure de force pour leur fabrication Download PDF

Info

Publication number
WO2021155151A1
WO2021155151A1 PCT/US2021/015713 US2021015713W WO2021155151A1 WO 2021155151 A1 WO2021155151 A1 WO 2021155151A1 US 2021015713 W US2021015713 W US 2021015713W WO 2021155151 A1 WO2021155151 A1 WO 2021155151A1
Authority
WO
WIPO (PCT)
Prior art keywords
moiety
receptor
vegfr
compound
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/015713
Other languages
English (en)
Inventor
Zheng Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Methodist Hospital System
Original Assignee
Methodist Hospital System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methodist Hospital System filed Critical Methodist Hospital System
Publication of WO2021155151A1 publication Critical patent/WO2021155151A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

  • the disclosed subject matter relates generally to force measurement platform to probe the distribution and distance of the cell surface receptors and using the same to make multivalent ligands targeting said receptors.
  • Multivalency governs many biological interactions and has been widely applied to synthetic compounds in support of targeted molecular imaging and drug therapy.
  • a number of multivalent binding mechanisms could be used to acquire high binding affinity, including chelate effect, statistical effect, steric stabilization, subsite binding, and receptor clustering.
  • the type of multivalent binding is largely determined by the selection of linkers tethering active entities. Although proper architectural design to support multiple binding plays a key role for the affinity, the length of the linker largely determines the statistical or the chelate effect in the interactions (Figure 1).
  • In terms of multivalent ligands targeting cell-surface receptors however, lack of knowledge on receptor distribution and distance in live cells often impedes the rational selection of linkers and scaffold architectures to fit into the relevant binding mechanisms for construction of multivalent ligands.
  • VEGFR vascular endothelial growth factor receptors
  • the methods can also be used to determine the spatial information of other cell-surface receptors such as PD-L1, EphB4 in cancer cells, PD1 CTLA4 in T cells, integrin, angiotensin-converting enzyme (ACE) (such as in SARS-Cov-2 infection), estrogen receptor (ER), or a combination thereof.
  • PD-L1, EphB4 in cancer cells
  • PD1 CTLA4 in T cells
  • integrin integrin
  • ACE angiotensin-converting enzyme
  • ER estrogen receptor
  • the method for determining the spatial distribution of receptors on a cell comprises functionalizing an AFM tip with one or more receptor binding moieties to form a functionalized AFM tip; contacting the functionalized AFM tip with the cell to facilitate binding of the one or more receptor binding moieties with the receptors and form a binder-receptor complex; determining the number of each receptor distributed in an area of the AFM tip, and deriving a maximum distance between two neighboring receptors.
  • the method includes conjugating a receptor binding moiety to a functional group to form a functional-binder conjugate; functionalizing an AFM tip with the functional-binder conjugate or a diluted solution of the functional-binder conjugate to form a functionalized AFM tip; contacting the functionalized AFM tip with the cell to facilitate binding of the functional-binder conjugate with the receptors and form a binder-receptor complex; using adhesive force measurements to determine a dissociative force of an ensemble of the binder-receptor complex and of a single binder-receptor complex, determining the number of each receptor distributed in an area of the AFM tip, and deriving a maximum distance between two neighboring receptors using maximizing minimum algorithm.
  • the multivalent ligands can be such that each ligand target the same or a different receptor. Therefore, the receptors used in probing the spatial distribution can be the same or different.
  • the receptors can be selected from VEGFR, PD-L1, EphB4 (such as in cancer cells), EphA4, PD1 CTLA4 (such as in T cells), integrin, angiotensin-converting enzyme (ACE) (such as in SARS-Cov-2 infection), estrogen receptor (ER), or a combination thereof.
  • the receptor binding moiety can be selected from a small molecule therapeutic agent, a peptide, an antibody, an antibody fragment, a carbohydrate, an siRNA, a protein, a nucleic acid, an aptamer, a nanoparticle, a cytokine, a chemokine, a lymphokine, a lipid, a lectin, or a combination thereof.
  • the method for determining the spatial distribution of VEGFR in a cell comprises conjugating a VEGFR binding moiety to a functional group such as a thiol group to form a functional-binder conjugate; functionalizing an AFM tip with the functional-binder conjugate or a diluted solution of the functional-binder conjugate to form a functionalized AFM tip; contacting the functionalized AFM tip with the cell to facilitate binding of the functional-binder conjugate with VEGFR and form a binder-VEGFR complex; using adhesive force measurements to determine a dissociative force of an ensemble of the binder- VEGFR complex and of a single binder-VEGFR complex; determining the number of VEGFR distributed in an area of the AFM tip; and deriving a maximum distance between two neighboring VEGFR using maximizing minimum algorithm.
  • a functional group such as a thiol group
  • the methods for making the multivalent compounds can comprise determining the proximal receptor distance between two or more receptors on the cell surface using AFM; synthesizing a multivalent compound comprising a first moiety and a second moiety covalently linked by a first linker, Li, wherein the first moiety comprises one or more receptor binding moieties, and the second moiety comprises an additional one or more receptor binding moieties, and wherein the first linker has a length not substantially less than, equal to, or greater than the proximal receptor distance.
  • the two or more receptors can be the same or different, based on the receptors being targeted.
  • the first linker can have a length within 20%, preferably within 15%, more preferably within 10%, of the proximal receptor distance. Preferably, the first linker has a length within 5% of the proximal receptor distance.
  • the multivalent compounds can have a binding affinity to the receptor that is greater than 10 times, greater than 100 times, greater than 1,000 times, or greater than 2,000 times the binding affinity of an equivalent single- valent compound to the receptor.
  • the compound is produced by a spatial distribution method as described herein and comprises at least a first moiety and a second moiety covalently linked by a first linker, Li.
  • Each of the first moiety and the second moiety can comprise a receptor binding moiety for a receptor selected from VEGFR, PD-L1, EphB4 (such as in cancer cells), PD1 CTLA4 (such as in T cells), integrin, angiotensin-converting enzyme (ACE) (such as in SARS-Cov-2 infection), estrogen receptor (ER), or a combination thereof.
  • multivalent compounds that target vascular endothelial growth factor receptors (VEGFR) for therapy and imaging of VEGFR expression.
  • the multivalent compounds can be tetravalent and comprises a first moiety and a second moiety covalently linked by a first linker, Li, wherein the first moiety comprises two or more VEGFR binding moieties linked by a second linker, L2, and the second moiety comprises an additional two or more VEGFR binding moieties linked by a third linker, L3.
  • the geometry of the linkers, Li, L2, or L3, are such that they promote multi -binding of the VEGFR binding moieties to multiple receptors.
  • each of Li, L2, or L3 can independently have a length from 7 to 60 A, such as from 40 to 60 A, or from 7 to 25 A.
  • the VEGFR binding moieties can be selected from the group consisting of bevacizumab; sunitinib; aflibercept; pazopanib; axitinib; sorafenib; vandetanib; regorafenib; ramucirumab, and combination thereof.
  • R 1 independently for each occurrence, is selected from hydroxyl, halogen, C1-3 alkyl, Ci- 3 alkoxyl, C1-3 alkanoyloxy, trifluoromethyl, cyano, amino, ornitro;
  • R 2 independently for each occurrence, is selected from hydrogen, hydroxyl, halogen, nitro, trifluoromethyl, cyano, C1-3 alkyl, C1-3 alkoxyl, C1-3 alkylthio, or-NR 7 R 8 , wherein R 7 and R 8 , which can be the same or different, each represents hydrogen or C1-3 alkyl;
  • R 3 is absent or comprises a detectable moiety or therapeutic moiety; p is an integer from 1 to 4.
  • the detectable moiety can be a near-infrared label, a fluorescent label, a radiolabel, a magnetic spin resonance label, a chromophore, a VEGFR ligand, or any combination thereof.
  • the therapeutic moiety can be radioisotopes for radiation therapy such as Y-90 or Lu-177 etc. or a chemotherapy drug.
  • the cells expressing VEGFR can be cancer cells, hyperproliferative cells, or any combination thereof. In other embodiments, the cells expressing VEGFR can be present in an animal diagnosed with pulmonary hypertension or who had a transplantation procedure.
  • Figures 1A-1B show two effects that govern bivalent binding to cell-surface receptors: (Figure 1A) statistical effect, arisen from increased local concentration of active entities tethered by short linker in bivalent ligands; ( Figure IB) chelate effect, arisen from simultaneously binding multiple receptors by active entities tethered by long linker in bivalent.
  • Figures 2A-2B show structures of the ZD6474 probe and thiol PEG that were used in the functionalization of ATM tips ( Figure 2A), and a schematic drawing for AFM force measurement of ZD6474 binding to VEGFR ( Figure 2B). Tips functionalized by various concentrations of ZD6474 probe diluted with thiol PEG, such as the 100%-tip and 5%-tip depicted in Figure 2B were prepared.
  • Figures 3A-3F show the force measurement of ZD6474 to VEGFR in live HUVECs. Measurements that used AFM tips functionalized with 100% ( Figures 3 A, 3C, and 3E) and 5% ( Figures 3B, 3D, and 3F) concentration of ZD6474 probe are shown and compared. Figures 3A and 3B show 3D height images of the cells obtained during the AFM force measurement;
  • Figures 3C and 3D show adhesive force mapping presented as 3D images corresponding to the height images in each group;
  • Figures 3E and 3F show histograms of ZD6474/VEGFR specific dissociative forces obtained from statistics of the area presented as the specific binding. 1024 histogram bins were used.
  • Figure 4 is a scheme showing chemical structures of compounds ZD-2, ZD-3, ZD-4, and
  • Figure 5 shows competition binding curves of compounds ZD-1 through -5 to HUVECs.
  • 64 Cu-ZD6474 was used as binding probe and the ZD compound from the design was individually supplemented as competition agent.
  • Figures 6A-6C show whole-body microPET/CT image of U87 glioblastoma-bearing mice.
  • Figure 6A shows representative PET/CT images of the tumor-bearing mice were displayed 24 h p.i. of 64 CU-ZD6474 and 64 Cu-ZD4 radiotracers. Tumor is indicated by a white arrowhead.
  • Figure 6C shows the imaged U87 glioblastoma xenograft was histologically studied using hematoxylin and eosin (H&E) and VEGFR2-antibody immunohistochemistry (VEGFR2 IHC) staining.
  • Figure 7 shows therapy data obtained from a triple native breast cancer model after administering 177 Lu-DiZD and anti-PDl.
  • Figure 8 is a flow diagram showing method of using AFM to design conforming compounds.
  • Figure 9 shows AFM height and force mapping of HUVEC cells using 100% IA monomer functionalized AFM tip.
  • Figure 10 shows AFM height and force mapping of MDA-MB-468 cells using 100% ephb4 monomer functionalized AFM tip.
  • Ranges may be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. Unless stated to the contrary, the term “about” means within 5%, e.g., within 1, 2, 3, or 4 % of the stated value, or less.
  • “Optional” or “optionally” means that the subsequently described event or circumstance does or does not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
  • the phrase “optionally substituted alkyl” means that the alkyl group is or is not substituted and that the description includes both unsubstituted lower alkyl and lower alkyl where there is substitution.
  • an “effective amount”, e.g., of the compounds or compositions described herein, refers to an amount of the compound in a composition or formulation which, when administered as part of a desired dosage regimen, brings about a change, e.g., in the rate of cell proliferation and/or the state of differentiation of a cell and/or rate of survival of a cell according to clinically acceptable standards for the disorder to be treated or, e.g., is taken up in a sufficient amount by VEGFR expressing cells such that the cells can be imaged by confocal microscopic imaging, CT imaging, PET imaging, MRI, or any combination thereof according to clinically acceptable standards for imaging cells.
  • “Pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues, organs, and/or bodily fluids of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable materials are known to those of ordinary skill in the art.
  • Half maximal inhibitory concentration refers to a measure of the effectiveness of a compound in inhibiting biological or biochemical function. This quantitative measure indicates how much of a particular drug or other substance (inhibitor) is needed to inhibit a given biological process (or component of a process, i.e. an enzyme, cell, cell receptor or microorganism) by half.
  • ICso represents the concentration of a drug that is required for 50% inhibition in vitro. The ICso can be determined using a variety of assays known in the art.
  • “Analog” and “derivative” are used herein interchangeably and refer to a compound that possesses the same core as the parent compound, but differs from the parent compound in bond order, the absence or presence of one or more atoms and/or groups of atoms, and combinations thereof.
  • the derivative can differ from the parent compound, for example, in one or more substituents present on the core, which can include one or more atoms, functional groups, or substructures.
  • a derivative can be imagined to be formed, at least theoretically, from the parent compound via chemical and/or physical processes.
  • “Aliphatic”, as used herein, refers to saturated or unsaturated groups containing carbon and hydrogen, including straight-chain alkyl, alkenyl, or alkynyl groups, branched-chain alkyl, alkenyl, or alkynyl groups, cycloalkyl, cycloalkenyl, or cycloalkynyl (alicyclic) groups, alkyl substituted cycloalkyl, cycloalkenyl, or cycloalkynyl groups, and cycloalkyl substituted alkyl, alkenyl, or alkynyl groups.
  • a straight chain or branched chain aliphatic group has 30 or fewer carbon atoms in its backbone (e.g, C1-C30 for straight chain, C3- C30 for branched chain), more preferably 20 or fewer carbon atoms, more preferably 12 or fewer carbon atoms, and most preferably 8 or fewer carbon atoms.
  • the chain has 1-6 carbons.
  • preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 5, 6, or 7 carbons in the ring structure. The ranges provided above are inclusive of all values between the minimum value and the maximum value.
  • alkyl includes both “unsubstituted alkyls” and “substituted alkyls”, the latter of which refers to alkyl moieties having one or more substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
  • substituents include, but are not limited to, halogen, hydroxyl, carbonyl (such as a carboxyl, alkoxy carbonyl, formyl, or an acyl), thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, a phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, aralkyl, or an aromatic or heteroaromatic moiety.
  • carbonyl such as a carboxyl, alkoxy carbonyl, formyl, or an acyl
  • thiocarbonyl such as a thioester, a
  • lower alkyl as used herein means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six carbon atoms in its backbone structure. Likewise, “lower alkenyl” and “lower alkynyl” have similar chain lengths. Preferred alkyl groups are lower alkyls.
  • the alkyl groups can also contain one or more heteroatoms within the carbon backbone. Examples include oxygen, nitrogen, sulfur, and combinations thereof. In certain embodiments, the alkyl group contains from one to four heteroatoms.
  • heteroalkyl refers to straight or branched chain, or cyclic carbon-containing radicals, or combinations thereof, containing at least one heteroatom. Suitable heteroatoms include, but are not limited to, O, N, Si, P, Se, B, and S, wherein the phosphorous and sulfur atoms are optionally oxidized, and the nitrogen heteroatom is optionally quatemized. Heteroalkyls can be substituted as defined above for alkyl groups.
  • alkylthio refers to an alkyl group, as defined above, having a sulfur radical attached thereto.
  • the “alkylthio” moiety is represented by one of -S- alkyl, -S-alkenyl, and -S-alkynyl.
  • Representative alkylthio groups include methylthio, ethylthio, and the like.
  • alkylthio also encompasses cycloalkyl groups, alkene and cycloalkene groups, and alkyne groups.
  • Arylthio refers to aryl or heteroaryl groups. Alkylthio groups can be substituted as defined above for alkyl groups.
  • Alkenyl and Alkynyl refer to unsaturated aliphatic groups containing one or more double or triple bonds analogous in length (e.g., C2-C30) and possible substitution to the alkyl groups described above.
  • Aryl refers to 5-, 6- and 7-membered aromatic rings.
  • the ring can be a carbocyclic, heterocyclic, fused carbocyclic, fused heterocyclic, bicarbocyclic, or biheterocyclic ring system, optionally substituted as described above for alkyl.
  • “Ar”, as used herein, includes 5-, 6- and 7-membered single-ring aromatic groups that can include from zero to four heteroatoms.
  • Examples include, but are not limited to, benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine.
  • aryl groups having heteroatoms in the ring structure can also be referred to as
  • heteroaryl “aryl heterocycles”, or “heteroaromatics”.
  • the aromatic ring can be substituted at one or more ring positions with such substituents as described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, — CF 3 , and — CN.
  • Ar also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are “fused rings”) wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocycles, or both rings are aromatic.
  • Alkylaryl refers to an alkyl group substituted with an aryl group (e.g., an aromatic or hetero aromatic group).
  • Heterocycle refers to a cyclic radical attached via a ring carbon or nitrogen of a monocyclic or bi cyclic ring containing 3-10 ring atoms, and preferably from 5-6 ring atoms, containing carbon and one to four heteroatoms each selected from non-peroxide oxygen, sulfur, and N(Y) wherein Y is absent or is H, O, (C ) alkyl, phenyl or benzyl, and optionally containing one or more double or triple bonds, and optionally substituted with one or more substituents.
  • heterocycle also encompasses substituted and unsubstituted heteroaryl rings.
  • heterocyclic ring examples include, but are not limited to, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4a//-carbazolyl. carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H.GH- 1 5.2-dithia/inyl.
  • quinoxalinyl quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6//- 1.2.5- thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl and xanthenyl.
  • Heteroaryl refers to a monocyclic aromatic ring containing five or six ring atoms containing carbon and 1, 2, 3, or 4 heteroatoms each selected from non-peroxide oxygen, sulfur, and N(Y) where Y is absent or is H, O, (Ci-Ce) alkyl, phenyl or benzyl.
  • Non- limiting examples of heteroaryl groups include furyl, imidazolyl, triazolyl, triazinyl, oxazoyl, isoxazoyl, thiazolyl, isothiazoyl, pyrazolyl, pyrrolyl, pyrazinyl, tetrazolyl, pyridyl, (or its N- oxide), thienyl, pyrimidinyl (or its N-oxide), indolyl, isoquinolyl (or its N-oxide), quinolyl (or its N-oxide) and the like.
  • heteroaryl can include radicals of an ortho-fused bicyclic heterocycle of about eight to ten ring atoms derived therefrom, particularly a benz-derivative or one derived by fusing a propylene, trimethylene, or tetramethylene diradical thereto.
  • heteroaryl examples include, but are not limited to, furyl, imidazolyl, triazolyl, triazinyl, oxazoyl, isoxazoyl, thiazolyl, isothiazoyl, pyraxolyl, pyrrolyl, pyrazinyl, tetrazolyl, pyridyl (or its N- oxide), thientyl, pyrimidinyl (or its N-oxide), indolyl, isoquinolyl (or its N-oxide), quinolyl (or its N-oxide), and the like.
  • alkoxyl refers to an alkyl group, as defined above, having an oxygen radical attached thereto.
  • Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like.
  • An “ether” is two hydrocarbons covalently linked by an oxygen. Accordingly, the substituent of an alkyl that renders that alkyl an ether is or resembles an alkoxyl, such as can be represented by one of -O-alkyl, -O-alkenyl, and -O-alkynyl.
  • Aroxy can be represented by -O-aryl or O-heteroaryl, wherein aryl and heteroaryl are as defined below.
  • the alkoxy and aroxy groups can be substituted as described above for alkyl.
  • amine and “amino” are art-recognized and refer to both unsubstituted and substituted amines, e.g., a moiety that can be represented by the general formula:
  • R9, Rio, and R'10 each independently represent a hydrogen, an alkyl, an alkenyl, -(CEhV-R's or R9 and Rio taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure;
  • R'x represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a poly cycle; and
  • m is zero or an integer in the range of 1 to 8.
  • only one of R9 or Rio can be a carbonyl, e.g., R9, Rio and the nitrogen together do not form an imide.
  • the term “amine” does not encompass amides, e.g., wherein one of R9 and Rio represents a carbonyl.
  • R9 and Rio each independently represent a hydrogen, an alkyl or cycloalkyl, an alkenyl or cycloalkenyl, or alkynyl.
  • alkylamine as used herein means an amine group, as defined above, having a substituted (as described above for alkyl) or unsubstituted alkyl attached thereto, i.e., at least one of R9 and Rio is an alkyl group.
  • the term “amido” is art-recognized as an amino-substituted carbonyl and includes a moiety that can be represented by the general formula -CONR9R10 wherein R9 and Rio are as defined above.
  • Halogen refers to fluorine, chlorine, bromine, or iodine.
  • Ni refers to -NO2.
  • “Sulfhydryl”, as used herein, refers to -SH.
  • Haldroxyl refers to -OH.
  • carbonyl is art-recognized and includes such moieties as can be represented by the general formula -CO-XR11, or -X-CO- R'11, wherein X is a bond or represents an oxygen or a sulfur, and R11 represents a hydrogen, an alkyl, a cycloalkyl, an alkenyl, an cycloalkenyl, or an alkynyl, R'11 represents a hydrogen, an alkyl, a cycloalkyl, an alkenyl, an cycloalkenyl, or an alkynyl. Where X is an oxygen and R11 or R'11 is not hydrogen, the formula represents an “ester”.
  • X is an oxygen and R11 is as defined above, the moiety is referred to herein as a carboxyl group, and particularly when R11 is a hydrogen, the formula represents a “carboxylic acid”. Where X is an oxygen and R'11 is hydrogen, the formula represents a “formate”. In general, where the oxygen atom of the above formula is replaced by sulfur, the formula represents a “thiocarbonyl” group.
  • substituted refers to all permissible substituents of the compounds described herein.
  • the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds.
  • Illustrative substituents include, but are not limited to, halogens, hydroxyl groups, or any other organic groupings containing any number of carbon atoms, preferably 1-14 carbon atoms, and optionally include one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats.
  • substituents include alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halo, hydroxyl, alkoxy, substituted alkoxy, phenoxy, substituted phenoxy, aryloxy, substituted aryloxy, alkylthio, substituted alkylthio, phenylthiol, substituted phenylthio, arylthio, substituted arylthio, cyano, isocyano, substituted isocyano, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, sulfonyl, substituted sulfonyl, sulfonic acid, phosphoryl, substituted phosphoryl, phosphonyl, substituted phosphony
  • substitution or “substituted” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, i.e. a compound that does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.
  • Such receptors can include vascular endothelial growth factor receptor (VEGFR), PD-L1, Ephrin type-B receptor 4 (EphB4), PD1 CTLA4 in T cells, integrin, angiotensin-converting enzyme (ACE) (such as in SARS-Cov-2 infection), estrogen receptor (ER), or a combination thereof.
  • VEGFR vascular endothelial growth factor receptor
  • EphB4 Ephrin type-B receptor 4
  • PD1 CTLA4 in T cells
  • integrin integrin
  • ACE angiotensin-converting enzyme
  • ER estrogen receptor
  • the compounds can contain two or more (such as 2, 3, or 4) receptor binding moieties (such as two or more VEGFR binding moieties) and at least one linker.
  • the compounds can contain two or more receptor binding moieties (such as two or more VEGFR binding moieties), at least one linker, and one or more detectable moieties.
  • the compounds can contain two or more receptor binding moieties (such as two or more VEGFR binding moieties), at least one linker, and one or more therapeutic moieties.
  • the compounds can contain two or more receptor binding moieties (such as two or more VEGFR binding moieties), at least one linker, one or more detectable moieties, and one or more therapeutic moieties.
  • the detectable moiety can be the therapeutic moiety.
  • the at least one linker covalently couples the moieties in the compounds.
  • the general structure of the compounds disclosed herein can be represented as (RBM) X - Ln or (RBM)x-Ln-(DTM)y, where RBM is a receptor binding moiety, L is a linker, DTM is a detectable moiety and/or a therapeutic moiety, x is an integer from 2 to 5, n is an integer from 1 to 5, and y is an integer from 1 to 5.
  • the compounds can be represented as (VBM)x-Ln or (VBM)x-L n -(DTM)y, where VBM is a VEGFR binding moiety, L is a linker,
  • DTM is a detectable moiety and/or a therapeutic moiety
  • x is an integer from 2 to 5
  • n is an integer from 1 to 5
  • y is an integer from 1 to 5.
  • the compounds disclosed herein can be represented as (RBM)2-L, (RBM)3-L2, (RBM)4-L3, (RBM)2-L-DTM, (RBM) 3 -L 2 -DTM, (RBM)4-L 3 -DTM, (RBM) 2 -L-(DTM) 2 , (RBM) 2 -L-(DTM) 3 , RBM-L-(DTM) 3 , (VBM) 2 -L, (VBM) 3 -L 2 , (VBM) 4 -L 3 , (VBM) 2 -L-DTM, (VBM) 3 -L 2 -DTM, (VBM)4-L 3 -DTM, (VBM) 2 -L-(DTM) 2 , (VBM
  • the compounds can contain two or more receptor binding moieties and at least one linker.
  • the receptor binding moieties can be selected from a small molecule therapeutic agent, a peptide, an antibody, an antibody fragment, a carbohydrate, an siRNA, a protein, a nucleic acid, an aptamer, a nanoparticle, a cytokine, a chemokine, a lymphokine, a lipid, a lectin, or a combination thereof.
  • the compounds can also contain two or more receptor binding moieties, at least one linker, and one or more detectable moieties.
  • the compounds can also contain two or more receptor binding moieties, at least one linker, and one or more therapeutic moieties.
  • the compounds can also contain two or more receptor binding moieties, at least one linker, one or more detectable moieties, and one or more therapeutic moieties.
  • the compounds can contain two or more EphB4 binding moieties and at least one linker.
  • the compounds can also contain two or more EphB4binding moieties, at least one linker, and one or more detectable moieties.
  • the compounds can also contain two or more EphB4binding moieties, at least one linker, and one or more therapeutic moieties.
  • the compounds can also contain two or more EphB4binding moieties, at least one linker, one or more detectable moieties, and one or more therapeutic moieties.
  • the compounds can contain four or more VEGFR binding moieties and at least one linker.
  • the compounds can also contain four or more VEGFR binding moieties, at least one linker, and one or more detectable moieties.
  • the compounds can also contain four or more VEGFR binding moieties, at least one linker, and one or more therapeutic moieties.
  • the compounds can also contain four or more VEGFR binding moieties, at least one linker, one or more detectable moieties, and one or more therapeutic moieties.
  • the compounds include at least two linkers or at least three linkers. In some embodiments, the compounds contain at least four VEGFR binding moieties and at least three linkers.
  • the compounds disclosed herein are tetravalent compounds comprising a first moiety and a second moiety covalently linked by a first linker, Li.
  • the first moiety in the compound can comprise two or more VEGFR binding moieties, wherein the two or more VEGFR binding moieties are linked by a second linker, L 2 .
  • the second moiety in the compound can comprise an additional two or more VEGFR binding moieties, wherein the additional two or more VEGFR binding moieties are linked by a third linker, L 3 .
  • Ephrin type-B receptor 4 (EphB4) makes up the largest subgroup of the receptor tyrosine kinase family and emerges as critical regulators postnatal angiogenic remodeling and tumor neovascularization.
  • EphB4 binding moieties is preferably any compound that is a potent antagonist of EphB4, with inhibits the binding of ephrin-B2 to murine EphB4 receptors.
  • the EphB4 binding moiety can include a peptide such as Asn-Tyr-Leu-Phe-Ser-Pro- Asn-Gly -Pro-lie- Ala- Arg-Ala-Trp or Tyr-Asn-Tyr-Leu-Phe-Ser-Pro-Asn-Gly-Pro-Ile-Ala-Arg- Ala-Trp (TNYLFSPNGPIARAW, designated as TNYL-RAW).
  • TNYLFSPNGPIARAW TNYL-RAW
  • EphB4 binding moieties can be coupled to one or more linkers, optionally comprising a detectable moiety or therapeutic moiety.
  • one or more EphB4 binding moieties can be coupled to one or more ephrin type-A receptor 4 (EphA4) binding moieties via a linker.
  • EphA4 binding moiety can be a peptide.
  • the EphB4 binding moiety can include a peptide such as
  • Ephrin type-B receptor 4 (EphB4) binding moieties include kinase inhibitors (such as anilinopyrimidine derivatives, benzenesulfonamide derivatives, XL647 also known as EXEL-7647, bis-anilino-pyrimidine derivatives, and xanthine derivatives); inhibitors of Eph expression (such as oligonucleotides); inhibitors of Eph-ephrin interactions (such as TNYL-RAW peptide, APY-d2-4, and small linear peptides (MW 600-700 Da), and monoclonal antibodies (such as mAh 131, mAh 147).
  • kinase inhibitors such as anilinopyrimidine derivatives, benzenesulfonamide derivatives, XL647 also known as EXEL-7647, bis-anilino-pyrimidine derivatives, and xanthine derivatives
  • inhibitors of Eph expression such as oligon
  • Integrin is a transmembrane receptor and activate signal transduction pathways that mediate cellular signals such as regulation of the cell cycle, organization of the intracellular cytoskeleton, and movement of new receptors to the cell membrane.
  • the integrin binding moieties is preferably any compound that is a potent antagonist of integrin.
  • the integrin binding moiety can include a small molecule having a structure as shown below:
  • two integrin binding moieties can be coupled to one or more linkers, optionally comprising a detectable moiety or therapeutic moiety.
  • the integrin binding moiety can include a small molecule dimer such as
  • integrin binding moieties can include the anti-aV 3 antibody etaracizumab (MEDI-522); anti-aV antibodies (such as intetumumab (CNT095) or abituzumab (EMD 525797/DI 17E6)); hhR-a5b 1 integrin antibody M200/volociximab; endogenous antagonists such as the peptides endostatin, tumstatin, or angiostatin; Arg-Gly- Asp-based cyclic peptide cilengitide (EMD121974) targeting anb3/anb5; o ⁇ l-blocking non Arg-Gly-Asp-based peptide ATN-161; peptidomimetics targeting anb3, anb5, and a5b1 (such as SCH221153, BCH-15046, SJ749, and JSM6427).
  • anti-aV 3 antibody etaracizumab etaracizumab
  • Angiotensin-Converting Enzyme acts as a host receptor for example in SARS- Cov-2 infection, which occurs by using the viral S (spike) protein receptor-binding domain binding to ACE2 to enter the host cell.
  • ACE inhibitors include benazepril (Lotensin), captopril, enalapril (Vasotec), fosinopril, lisinopril (Prinivil, Zestril), moexipril, perindopril, quinapril (Accupril), Ramipril (Altace), and trandolapril.
  • Estrogens are a class of steroid hormones that regulate the growth, development, and physiology of the human reproductive system. Estrogens are also involve in the neuroendocrine, skeletal, adipogenesis, and cardiovascular systems. Estrogen signaling pathways are selectively stimulated or inhibited depending on a balance between the activities of estrogen receptor (ER) a or ER in target organs. Research has identified membrane ER signaling mediating many physiological and pathological processes and functions in organs, such as fertility, reproductive organs, mammary gland, male reproduction, bone development and maintenance, cardiovascular tissues and metabolism, brain, and behavior.
  • ER estrogen receptor
  • estrogen receptor binding moieties can be found in Sharma D. et al, Chem Cent J. 2018; 12: 107 which is hereby incorporated herein by reference. Specific examples include heterocyclic analogues (such as diben/o
  • f]thiepines analogues diphenylmethane skeleton, conjugated heterocyclic scaffolds, aromatase inhibitors/selective estrogen receptor modulator, norendoxifen, furan derivatives, fulvestrant, diphenylmethane, diphenylmethyelene, diphenylheptane, diphenyl amine analogs and tri aryl ethylene analogs, coumarin conjugates, coumarin-chalcone hybrids, inverse agonist, steroidal analogs, reseveratrol (phytoestrogen) analogs, triarylethylene analogs, isoflavone analogs, indole derivatives, pyrazole derivatives, hydrazones, isoquinoline derivatives, anilinonicotinyl linked pyrazolo[l,5- ajpyrimidine conjugate, bis(hydroxyphenyl)azoles, quinoline analogues, isoflavone derivatives as aromatase inhibitor
  • VEGFR binding moiety VEGFR binding moiety
  • the VEGFR binding moieties is preferably any compound that inhibits VEGFR.
  • the VEGFR binding moieties can be independently selected from the group consisting of bevacizumab; sunitinib; aflibercept; pazopanib; axitinib; sorafenib; vandetanib; regorafenib; ramucirumab, and combination thereof.
  • the VEGFR binding moieties has a structure as shown in Formula 1,
  • R 1 can be hydroxyl, halogen, C1-3 alkyl, C1-3 alkoxyl, C1-3 alkanoyloxyl, trifluoromethyl, cyano, amino, or nitro;
  • R 2 and R 2 can be, independent of one another, hydrogen, hydroxyl, halogen, nitro, trifluoromethyl, cyano, C1-3 alkyl, C1-3 alkoxyl, C1-3 alkylthio, or -NR 7 R 8 , wherein R 7 and R 8 , which can be the same or different, each represents hydrogen or C1-3 alkyl;
  • A can be oxygen, -CH2-, -S-, -SO-, -SO2-, -NR 7 CO-, -CONR 7 -, -SO2NR 7 -, -NR 7 S0 2 - or
  • Q can be nitrogen or -CH-; n is an integer from 1 to 5, for example, n can be 1, 2, 3, 4, or 5; and p is an integer from 1 to 4, for example, p can be 1, 2, 3, or 4.
  • R 1 can be a halogen, for example, Br or F. In other examples, R 1 can be hydroxyl, C1-3 alkyl, or C1-3 alkyl.
  • R 2 is preferably hydrogen. In still other examples, R 2 is preferably Ci-3 alkyl, or C1-3 alkoxyl. In yet further examples, A is preferably -O- and Q is preferably N. Also, in the disclosed compounds n is preferably 1 or 2 and p is preferably 1 or 2.
  • the VEGFR binding moiety has Formula 1-A, which corresponds to vandetanib (ZD-1). Formula 1-A.
  • VEGFR binding moieties can be coupled to one or more linkers, optionally comprising a detectable moiety or therapeutic moiety (R 3 ).
  • linkers optionally comprising a detectable moiety or therapeutic moiety (R 3 ).
  • R 3 therapeutic moiety
  • R 1 independently for each occurrence, is selected from hydroxyl, halogen, C1-3 alkyl, Ci- 3 alkoxyl, C1-3 alkanoyloxy, trifluoromethyl, cyano, amino, ornitro;
  • R 2 independently for each occurrence, is selected from hydrogen, hydroxyl, halogen, nitro, trifluoromethyl, cyano, C1-3 alkyl, C1-3 alkoxyl, C1-3 alkylthio, or-NR 7 R 8 , wherein R 7 and R 8 , which can be the same or different, each represents hydrogen or C1-3 alkyl;
  • R 3 is absent or comprises a detectable moiety or therapeutic moiety; p is an integer from 1 to 4.
  • the compound can have the Formula II, which corresponds to Formula I, where p is 2, R 1 is halogen (fluro and bromo), and R 2 is methoxy:
  • R 3 , Li, L2, and L3 in Formula II can be as described herein.
  • the compounds have Formula IIIA or IIIB:
  • D comprises the detectable moiety.
  • bivalent compounds that bind to VEGFR have been disclosed in U.S. Patent No. 10,011,587, the disclosure of which is hereby incorporated by reference in its entirety.
  • the bivalent compounds include a linker, the geometry of which is such that it promotes multi-binding of the VEGFR binding moieties to multiple receptors.
  • R 1 can be hydroxyl, halogen, C1-3 alkyl, C1-3 alkoxyl, C1-3 alkanoyloxyl, trifluoromethyl, cyano, amino, or nitro;
  • R 2' and R 2" can be, independent of one another, hydrogen, hydroxyl, halogen, nitro, trifluoromethyl, cyano, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylthio, or-NR 7 R 8 , wherein R 7 and R 8 , which can be the same or different, each represents hydrogen or C1-3 alkyl;
  • A can be oxygen, -CH2-, -S-, -SO-, -SO2-, -NR 7 CO-, -CONR 7 -, -SO2NR 7 -, -NR 7 S0 2 - or
  • Q can be nitrogen, or -CH-;
  • L is a linker
  • R 3 contains a detectable moiety, a therapeutic moiety, or both; n is an integer from 1 to 5, for example, n can be 1, 2, 3, 4, or 5; m is an integer from 1 to 5, for example, m can be 1, 2, 3, 4, or 5; and p is an integer from 1 to 4, for example, p can be 1, 2, 3, or 4.
  • the compound can have the Formula V, which correspond to Formula IV, where A is oxygen, Q is nitrogen, n is 1, and R 2 and R 5 are both hydrogen: wherein,
  • R 1 can be hydroxyl, halogen, C1-3 alkyl, C1-3 alkoxyl, C1-3 alkanoyloxyl, trifluoromethyl, cyano, amino or nitro;
  • R 2 can be, independent of one another, hydrogen, hydroxyl, halogen, nitro, trifluoromethyl, cyano, C1-3 alkyl, C1-3 alkoxyl, C1-3 alkylthio, or-NR 7 R 8 , wherein R 7 and R 8 , which can be the same or different, each represents hydrogen or C1-3 alkyl;
  • L is a linker
  • R 3 contains a detectable moiety, a therapeutic moiety, or both; m is an integer from 1 to 5, for example, m can be 1, 2, 3, 4, or 5; and p is an integer from 1 to 4, for example 1, 2, 3, or 4.
  • the compounds have Formula VI: Formula VI wherein,
  • R 6 is a detectable moiety, a therapeutic moiety, or both.
  • Compounds of Formula VII are also described herein: wherein,
  • R 1 can be hydroxyl, halogen, C1-3 alkyl, C1-3 alkoxyl, C1-3 alkanoyloxyl, trifluoromethyl, cyano, amino, or nitro;
  • R 2" can be hydrogen, hydroxy, halogen, nitro, trifluoromethyl, cyano, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylthio, or -NR 7 R 8 , wherein R 7 and R 8 , which can be the same or different, each represents hydrogen or C1-3 alkyl;
  • L is a linker
  • R 3 contains a detectable moiety, a therapeutic moiety, or both; and p is an integer from 1 to 4, for example, p can be 1, 2, 3, or 4.
  • the compounds have the following structures: Linker (L)
  • the compounds described herein contain a linker (L).
  • L a force measurement platform to probe the distribution and distance of the cell surface receptors (such as vascular endothelial growth factor receptors (VEGFR)) in live cells has been disclosed, which has been used to determine the geometry of appropriate linkers for distinct multivalent binding modes.
  • the linker can be of any nature, but provides a particular geometry for the multivalent binding moieties.
  • the length of the linker can be important in determining the statistical or the chelate effect for the interaction of the binding moieties to the receptors (such as VEGFR).
  • the multivalent binding compounds can include one or more linkers.
  • the compounds include a first linker, Li, a second linker, L2, and a third linker, L3.
  • the linkers can each independently have a length from 40 to 60 A, which defines the distance between two adjacent receptors (such as VEGFR) on the cell’s periphery.
  • each linker can have a length from 40 to 58 A, from 40 to 56 A, from 40 to 55 A, from 40 to 54 A, from 40 to 52 A, from 40 to 50 A, from 40 to 49 A, from 40 to 48 A, from 40 to 47 A, from 42 to 58 A, from 42 to 55 A, from 42 to 54 A, from 42 to 52 A, from 42 to 50 A, from 42 to 48 A, from 45 to 60 A, from 45 to 56 A, from 45 to 55 A, from 45 to 54 A, from 45 to 52 A, from 45 to 50 A, from 45 to 49 A, from 45 to 48 A, or from 45 to 47 A.
  • the binding of multivalent compounds comprising linkers with length similar or greater than the proximal receptor (such as VEGFR) distance in cells is believed to be dominated in binding by the chelating effect.
  • each linker can independently have a length from 7 to 25 A, which defines a distance shorter that the proximal receptor (such as VEGFR) distance on the cell’s periphery.
  • each linker can independently have a length from 7 to 22 A, from
  • Li can have a length from 40 to 60 A (for e.g., from 40 to 58 A, from 40 to 56 A, from 40 to 55 A, from 40 to 54 A, from 40 to 52 A, from 40 to 50 A, from 40 to 49 A, from 40 to 48 A, from 40 to 47 A, from 42 to 58 A, from 42 to 55 A, from 42 to 54 A, from 42 to 52 A, from 42 to 50 A, from 42 to 48 A, from 45 to 60 A, from 45 to 56 A, from 45 to 55 A, from 45 to 54 A, from 45 to 52 A, from 45 to 50 A, from 45 to 49 A, from 45 to 48 A, or from 45 to 47 A).
  • 40 to 60 A for e.g., from 40 to 58 A, from 40 to 56 A, from 40 to 55 A, from 40 to 54 A, from 40 to 52 A, from 40 to 50 A, from 40 to 49 A, from 40 to 48 A, or from 45 to 47 A).
  • each of L2 and L3 can independently have a length of from 7 to 60 A.
  • L2 and L3 can independently have similar lengths compared to the first linker (for e.g., from 40 to 60 A, from 40 to 58 A, from 40 to 56 A, from 40 to 55 A, from 40 to 54 A, from 40 to 52 A, from 40 to 50 A, from 40 to 49 A, from 40 to 48 A, from 40 to 47 A, from 42 to 58 A, from 42 to 55 A, from 42 to 54 A, from 42 to 52 A, from 42 to 50 A, from 42 to 48 A, from 45 to 60 A, from 45 to 56 A, from 45 to 55 A, from 45 to 54 A, from 45 to 52 A, from 45 to 50 A, from 45 to 49 A, from 45 to 48 A, or from 45 to 47 A).
  • L2 and L3 can independently have shorter lengths compared to the first linker (for e.g., from 7 to 25 A, from 7 to 22 A, from 7 to 20 A, from 7 to 18 A, from 7 to 16 A, from 7 to 14 A, from 8 to 25 A, from 8 to 24 A, from 8 to 22 A, from 8 to 20 A, from 8 to 18 A, from 8 to 16 A, from 8 to 14 A, from 10 to 25 A, from 10 to 24 A, from 10 to 22 A, from 10 to 20 A, from 10 to 18 A, from 10 to 16 A, from 10 to 14 A, from 12 to 25 A, from 12 to 24 A, from 12 to 22 A, from 12 to 20 A, from 12 to 18 A, from 12 to 16 A, or from 12 to 14 A).
  • the first linker for e.g., from 7 to 25 A, from 7 to 22 A, from 7 to 20 A, from 7 to 18 A, from 7 to 16 A, from 7 to 14 A, from 8 to 25 A, from 8 to 24 A, from 8 to 22
  • the linker is polyfunctional, such as bi-functional, tri-functional, or tetra-functional molecules, and can be used to covalently couple the two or more receptor (such as VEGFR) binding moieties, the one or more detectable moieties, and one or more therapeutic moieties of the disclosed compounds.
  • the linker can be attached to any part of the receptor binding moiety so long as the point of attachment does not interfere with the biological activity, for example, the anti-tumor and/or anti-inflammatory activity of the compounds described herein.
  • Li covalently links the first moiety to the second moiety in the compounds disclosed;
  • L2 links the two or more receptor binding moieties in the first moiety; and
  • L3 links the two or more additional receptor binding moieties in the second moiety.
  • Li, L2, and L3 can be structurally similar, having similar chemical identity.
  • Li, L2, and L3 can be segments (components) of the same (a single) molecule, but are so described to differentiate connections.
  • the compound can include a single linker that is a branched compound (such as a branched alkyl or branched amide), wherein each branch represents a linker that connects the receptor (such as VEGFR) moiety to the main chain of the linker.
  • a linker comprising Li, L2, and L3 can be the same molecule with different segments.
  • the linker is flexible. In some embodiment, the linker is stable and biocompatible. In some embodiments, the covalent bond formed between the linker and the receptor binding moiety and/or the detectable moiety is stable. Stable, as used herein refers to a covalent bond that remains at least 70%, preferably at least 80%, more preferably at least 90% intact in aqueous solution at temperatures ranging from about 0 °C to about 100 °C, at a pH ranging from about 2 to about 12, for at least 1 hour. The covalent bond formed between the linker and the receptor binding moiety and/or the detectable moiety is hydrolytically and reductively stable.
  • a heteroatom e.g., O, N, or S
  • Suitable linkers include but are not limited to oxygen, sulfur, carbon, nitrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted alkoxyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted ether, substituted or unsubstituted amine, substituted or unsubstituted diamine, substituted or unsubstituted amide, substituted or unsubstituted alkylamine, substituted or unsubstituted thioether, substituted or unsubstituted carboxylates, substituted or unsubstituted polymer, derivatives or combinations thereof.
  • the linkers, Li, L2, and L3, can be selected from R 14 , C(0)R 14 C(0), C(0)0R 14 0C(0), C(0)R 14 N, C(0)0R 14 NH, NHR 14 NH, C(0)NHR 14 NHC(0), HNC(0)R 14 C(0)NH, C(0)CHNHR 14 NHCHC(0), C(S)OR 14 OC(S); wherein R 14 is O, S, C1-C20 alkyl; C1-C20 heteroalkyl; C1-C20 alkylamine; C1-C20 alkoxyl; Ci-C2o alkanoyloxyl; polyalkyleneoxy; or C1-C20 alkylamido, any of which can be optionally substituted with one or more substituents including halogen, alkoxyl, alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, amine, alkylamine, dialkylamine,
  • the linkers, Li, L2, and L3, can be selected fromN(R 14 )3,
  • the linkers, Li, L2, and L3, can be selected from -(CO- R 14 ) 2 N(R 14 ), -(R 14 ) 3 N, -(S0 2 R 14 ) 2 NR 14 , -(S0R 14 ) 2 NR 14 , -(0R 14 ) 2 NR 14 , -(0-C0-R 14 ) 2 NR 14 , -(CO- 0-R 14 ) 2 NR 14 , -(C0-R 14 ) 2 CH(R 14 ), -(R 14 ) 3 CH, -(S0 2 R 14 ) 2 CH(R 14 ), -(S0R 14 ) 2 CH(R 14 ), -(O-CO- R 14 )2CH(R 14 ), or -(OR 14 )2CH(R 14 ), wherein R 14 is independently selected from, for each occurrence, a bond, C1-C20 alkyl; C1-C20 heteroalkyl, Ci-
  • the linkers Li, L2, and L 3 are selected from is -(NHCO-R 14 ) 3 Ar, - (CONH-R 14 ) 3 Ar, -(CO-R 14 ) 3 Ar, wherein R 14 is independently selected from, for each occurrence, a bond, C1-C20 alkyl; C1-C20 heteroalkyl, Ci-C2o alkylamine, C1-C20 alkoxy, polyalkyleneoxy, Ci-C2o alkanoyloxy, or C1-C20 alkylamido; wherein R 14 is optionally substituted with one or more substituents independently selected from the group consisting of amino; alkylamino; dialkylamino; amido; alkylamido; alkoxyamido; polyalyleneoxyamido; aryl; heteroaryl; or combinations thereof.
  • the linkers Li, L2, and L 3 are selected from -(R 14 ) 3 CH, wherein each of R 14 is independently selected from a bond, carboxyl, C2-10 alkylcarboxyl.
  • the linker can be an amino acid.
  • the amino acid can be a natural or non-natural amino acid.
  • non-natural amino acid refers to an organic compound that is a congener of a natural amino acid in that it has a structure similar to a natural amino acid so that it mimics the structure and reactivity of a natural amino acid.
  • the non-natural amino acid can be a modified amino acid, and/or amino acid analog, that is not one of the 20 common naturally occurring amino acids or the rare natural amino acids selenocysteine or pyrrolysine.
  • suitable amino acids include, but are not limited to, alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, a derivative, or combinations thereof.
  • Aminodicarboxylic acids include, but are not limited to, alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, a derivative, or combinations thereof.
  • Aminodicarboxylic acids include, but are not limited to,
  • the linker is an amino dicarboxylic acid.
  • the amino dicarboxylic acid can have from 2 to 30 carbon atoms.
  • suitable amino dicarboxylic acids include, but are not limited to, l,6-dicarboxylic-2-amino hexanoic acid, 1,7- dicarboxylic-2-amino heptanoic acid, l,8-dicarboxylic-2-amino octanoic acid, a-aminosuccinic acid, b-aminoglutaric acid, b-aminosebacic acid, 2,6-piperidine dicarboxylic acid, 2,5-pyrrole dicarboxylic acid, 2-carboxypyrrole-5-acetic acid, 2-carboxypiperidine-6-propionic acid, 2- aminoadipic acid, 3-aminoadipic acid, a-aminoazelaic acid, and 4-aminobenzene-l,3- dicarbox
  • the linker can be a dicarboxylic acid.
  • the dicarboxylic acid can have from 2 to 20 carbon atoms.
  • Examples of dicarboxylic acid include, but are not limited to, butanedioic acid, pentanedioic acid, hexanedioic acid, heptanedioic acid, octanedioic acid, nonanedioic acid, decanedioic acid, undecanedioic acid, dodecanedioic acid, tridecanedioic acid, 1,12-dodecanedicarboxylic acid, 1,15-pentadecanedicarboxylic acid, hexadecanedioic acid, and 1,15-pentadecanedicarboxylic acid.
  • the dicarboxylic acid is an halogenated dicarboxylic acid, hydroxy dicarboxylic acid, or
  • the linker can be a tricarboxylic acid or a derivative thereof.
  • the tricarboxylic acid can have from 2 to 30 carbon atoms.
  • the tricarboxylic acid can be aliphatic or cyclic. Examples of tricarboxylic acid include, but are not limited to, 2-phosphonobutane-l, 2, 4-tri carboxylic acid and 1,2,3-propane tricarboxylic acid.
  • the linker can be an alcohol or a derivative thereof.
  • the alcohol can be a diol, triol, amino alcohol, amino dialcohol, amino trialcohol, ethylene glycol, propylene glycol, or a derivative.
  • the alcohol can have from 2 to 30 carbon atoms.
  • suitable alcohols include, but are not limited to, triethanolamine, 2-aminoethanol, diisopropanolamine, triisopropanolamine, amino hexanol, 2-[(2-methoxyethyl)methylamino]- ethanol, propanolamine, /V-methylethanolamine, diethanolamine, butanol amine, isobutanolamine, pentanol amine, l-amino-3-(2-methoxy ethoxy)- 2-propanol, 2-methyl-4- (methylamino)- 2-butanol, 6-amino- 1 -hexanol, heptaminol, isoetarine, norepinephrine, sphingosine, phenylpropanolamine, derivatives, and combinations thereof.
  • Polymers include, but are not limited to, triethanolamine, 2-aminoethanol, diisopropanolamine, triisopropanolamine, amino he
  • the linker can be a polymer.
  • a wide variety of polymers and methods for forming the polymers are known in the art of polymer science. Polymers can be degradable or non-degradable polymers. Polymers can be natural or unnatural (synthetic) polymers. Polymers can be homopolymers or copolymers comprising two or more monomers.
  • copolymers can be random, block, or comprise a combination of random and block sequences.
  • the polymers can in some embodiments be linear polymers, branched polymers, or hyperbranched/dendritic polymers.
  • the polymers can also be present as a crossbnked particle or surface functionalized inorganic particle.
  • Suitable polymers include, but are not limited to poly(vinyl acetate), copolymers of styrene and alkyl acrylates, and copolymers of vinyl acetate and acrylic acid, polyvinylpyrrolidone, dextran, carboxymethylcellulose, polyethylene glycol, polyalkylene, polyanhydrides, poly(ester anhydrides), polyhydroxy acids, such as polylactide (PLA), polyglycobde (PGA), poly(lactide-co-glycobde) (PLGA), poly-3- hydroxybutyrate (PHB), poly-4-hydroxybutyrate (P4HB), polycaprolactone, polyacrylates and polymethacrylates; polyanhydrides; polyorthoesters; polysytyrene (PS), poly(ethylene-co-maleic anhydride), poly(ethylene maleic anhydride-co-L-dopamine), poly(ethylene maleic anhydride- co-phenylalanine), poly(ethylene maleic anhydride-
  • linkers include, but are not limited to, diamino compounds such as ethylenediamine, 1 ,2-propylenediamine, 1,5-pentanediamine, 1,6-hexanediamine, and the like.
  • Detectable Moiety and/or Therapeutic Moiety R 3
  • the disclosed compounds can also contain one or more detectable moieties and/or one or more therapeutic moieties, R 3 .
  • the detectable moiety can be the therapeutic moiety.
  • the detectable moiety can contain any detectable label. Examples of suitable detectable labels include, but are not limited to, a UV-Vis label, a near-infrared label, a luminescent group, a phosphorescent group, a magnetic spin resonance label, a photosensitizer, a photocleavable moiety, a chelating center, a heavy atom, a radioactive isotope, a isotope detectable spin resonance label, a paramagnetic moiety, a chromophore, or any combination thereof.
  • the label is detectable without the addition of further reagents.
  • the detectable moiety is a biocompatible detectable moiety, such that the compounds can be suitable for use in a variety of biological applications.
  • Biocompatible and “biologically compatible”, as used herein, generally refer to compounds that are, along with any metabolites or degradation products thereof, generally non-toxic to cells and tissues, and which do not cause any significant adverse effects to cells and tissues when cells and tissues are incubated (e.g., cultured) in their presence.
  • the detectable moiety can contain a luminophore such as a fluorescent label or near- infrared label.
  • a luminophore such as a fluorescent label or near- infrared label.
  • suitable luminophores include, but are not limited to, metal porphyrins; benzoporphyrins; azabenzoporphyrine; napthoporphyrin; phthalocyanine; polycyclic aromatic hydrocarbons such as perylene, perylene diimine, pyrenes; azo dyes; xanthene dyes; boron dipyoromethene, aza-boron dipyoromethene, cyanine dyes, metal-ligand complex such as bipyridine, bipyridyls, phenanthroline, coumarin, and acetylacetonates of ruthenium and iridium; acridine, oxazine derivatives such as benzophenoxazine; aza-an
  • luminophores include, but are not limited to, Pd (II) octaethylporphyrin; Pt (II)- octaethylporphyrin; Pd (II) tetraphenylporphyrin; Pt (II) tetraphenylporphyrin; Pd (II) meso- tetraphenylporphyrin tetrabenzoporphine; Pt (II) meso-tetrapheny metrylbenzoporphyrin; Pd (II) octaethylporphyrin ketone; Pt (II) octaethylporphyrin ketone; Pd (II) meso- tetra(pentafluorophenyl)porphyrin; Pt (II) meso-tetra (pentafluorophenyl
  • the detectable moiety can contain a radiolabel, also referred to herein as radioisotope.
  • the radiolabel can also be a therapeutic moiety, i.e., a radiolabel comprising a therapeutic radionuclide such as, 90 Y or 177 Lu.
  • suitable radiolabels include, but are not limited to, isotopes such as 18 F, 68 Ga, 64 Cu, 67 Cu, 89 Zr, m In, 124 I, 123 I, and 99m Tc.
  • the radiolabel can be chelated by a macrocyclic molecule.
  • macrocycbc molecules include, but are not limited to, 2,2',2"-(10-(2-((2,5-dioxopyrrolidin-l- yl)oxy)-2-oxoethyl)-l,4,7,10-tetraazacyclododecane-l,4,7-triyl)triacetic acid (DOTA) -based chelators, diethylene triamine pentaacetic acid (DTPA)-based chelators, and a derivative or a combination thereof.
  • DOTA diethylene triamine pentaacetic acid
  • DTPA diethylene triamine pentaacetic acid
  • the detectable moiety can contain a magnetic spin resonance label.
  • suitable spin resonance label include free radicals such as nitroxide-stable free radicals.
  • Stable free radicals of nitroxides are known in the art, see for example Keana, “Newer Aspects of Synthesis and Chemistry of Nitroxide Spin Labels”, Chemical Reviews, 1978, Vol. 78 No. 1, pp. 37-64, which disclosure is incorporated herein by reference.
  • Suitable nitroxides include, but are not limited to, those derived from 2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPO), 2, 2,5,5- tetramethylpyrroline-N-oxyl, and 4,4-dimethyloxazolidine-N-oxyl which is a doxyl nitroxide.
  • TEMPO 2,2,6,6-tetramethylpiperidine-N-oxyl
  • 2,5,5- tetramethylpyrroline-N-oxyl 2,5,5- tetramethylpyrroline-N-oxyl
  • 4,4-dimethyloxazolidine-N-oxyl which is a doxyl nitroxide.
  • nitroxides include, but are not limited to, doxyl nitroxides, proxyl nitroxides, azethoxyl nitroxides, imidazoline derived nitroxides, tetrahydrooxazine derived nitroxides, and the recently synthesized steroid nitroxides, and the like.
  • Spin labeling is understood to mean “spin label” as that is defined in the Keana article, namely when a nitroxide bearing molecule that is covalently attached to another molecule of interest, the nitroxide grouping does not significantly disturb the behavior of the system under study. Thus, the nitroxide molecule being paramagnetic, simply enhances the energy or excitation level subjected to the magnetic field during the magnetic resonance. Therapeutic Moiety
  • the disclosed compounds can also contain a therapeutic moiety.
  • the detectable moiety can be linked to a therapeutic moiety.
  • Therapeutic moiety refers to a group that when administered to a subject, will cure, or at least relieve to some extent, one or more symptoms of, a disease or disorder.
  • Therapeutic moieties include a wide variety of drugs, including antagonists, for example enzyme inhibitors, and agonists, for example a transcription factor which results in an increase in the expression of a desirable gene product (although as will be appreciated by those in the art, antagonistic transcription factors can also be used), are all included.
  • therapeutic moiety includes those agents capable of direct toxicity and/or capable of inducing toxicity towards healthy and/or unhealthy cells in the body.
  • the therapeutic moiety can be capable of inducing and/or priming the immune system against potential pathogens.
  • a number of mechanisms are possible including without limitation, (i) a radioisotope linked to a protein as is the case with a radiolabeled protein, (ii) an antibody linked to an enzyme that metabolizes a substance, such as a prodrug, thus rendering it active in vivo,
  • an antibody linked to a small molecule therapeutic agent (iii) an antibody linked to a small molecule therapeutic agent, (iv) a radioisotope, (v) a carbohydrate, (vi) a lipid, (vii) a thermal ablation agent, (viii) a photosensitizing agent, and (ix) a vaccine agent.
  • the therapeutic compound or moiety can be one that kills or inhibits cancer cells directly (e.g., cisplatin) or it can be one that can kill or inhibit a cancer cell indirectly (e.g., gold nanoparticles that kill or destroy cancer cells when heated using a light source).
  • the compounds can include therapeutic moieties including without limitation small molecules or drugs.
  • the drug is doxorubicin.
  • doxorubicin can be substituted with a doxorubicin analog such as fluorescein.
  • the spectroscopic signature of fluorescein UV absorbance (229 nm), visible absorbance (495 nm) and strong fluorescence (520 nm) makes it an inexpensive and easy molecule to monitor.
  • the therapeutic moiety can comprise a targeting moiety, such as a peptide.
  • the therapeutic moiety is a VEGFR ligand, such as vandetanib.
  • the compounds described herein can be formulated for enteral, parenteral, topical, or pulmonary administration.
  • the compounds can be combined with one or more pharmaceutically acceptable carriers and/or excipients that are considered safe and effective and can be administered to an individual without causing undesirable biological side effects or unwanted interactions.
  • the carrier is all components present in the pharmaceutical formulation other than the active ingredient or ingredients.
  • the compounds described herein can be formulated for parenteral administration.
  • parenteral administration means administration by any method other than through the digestive tract or non-invasive topical or regional routes.
  • parenteral administration can include administration to a patient intravenously, intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrapleurally, intratracheally, intravitreally, intratumorally, intramuscularly, subcutaneously, subconjunctivally, intravesicularly, intrapericardially, intraumbilically, by injection, and by infusion.
  • Parenteral formulations can be prepared as aqueous compositions using techniques known in the art.
  • such compositions can be prepared as injectable formulations, for example, solutions or suspensions; emulsions, such as water-in-oil (w/o) emulsions, oil-in-water (o/w) emulsions, and microemulsions thereof, liposomes, or emulsomes.
  • injectable formulations for example, solutions or suspensions
  • emulsions such as water-in-oil (w/o) emulsions, oil-in-water (o/w) emulsions, and microemulsions thereof, liposomes, or emulsomes.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, one or more polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), oils, such as vegetable oils (e.g., peanut oil, com oil, sesame oil, etc.), and combinations thereof.
  • polyols e.g., glycerol, propylene glycol, and liquid polyethylene glycol
  • oils such as vegetable oils (e.g., peanut oil, com oil, sesame oil, etc.), and combinations thereof.
  • Solutions and dispersions of the active compounds can be prepared in water or another solvent or dispersing medium suitably mixed with one or more pharmaceutically acceptable excipients including, but not limited to, surfactants, dispersants, emulsifiers, pH modifying agents, viscosity modifying agents, and combination thereof.
  • pharmaceutically acceptable excipients including, but not limited to, surfactants, dispersants, emulsifiers, pH modifying agents, viscosity modifying agents, and combination thereof.
  • Suitable surfactants can be anionic, cationic, amphoteric or nonionic surface active agents.
  • Suitable anionic surfactants include, but are not limited to, those containing carboxylate, sulfonate and sulfate ions.
  • anionic surfactants include sodium, potassium, ammonium of long chain alkyl sulfonates and alkyl aryl sulfonates such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium bis-(2-ethylthioxyl)-sulfosuccinate; and alkyl sulfates such as sodium lauryl sulfate.
  • Cationic surfactants include, but are not limited to, quaternary ammonium compounds such as benzalkonium chloride, benzethonium chloride, cetrimonium bromide, stearyl dimethylbenzyl ammonium chloride, polyoxyethylene and coconut amine.
  • nonionic surfactants include ethylene glycol monostearate, propylene glycol myristate, glyceryl monostearate, glyceryl stearate, polyglyceryl-4-oleate, sorbitan acylate, sucrose acylate, PEG-150 laurate, PEG-400 monolaurate, polyoxyethylene monolaurate, polysorbates, polyoxyethylene octylphenylether, PEG- 1000 cetyl ether, polyoxyethylene tridecyl ether, polypropylene glycol butyl ether, PoloxamerTM 401, stearoyl monoisopropanolamide, and polyoxyethylene hydrogenated tallow amide.
  • amphoteric surfactants include sodium N-dodecyl-. beta. -alanine, sodium N-lauryl-. beta. - iminodipropionate, myristoamphoacetate, lauryl betaine and lauryl sulfobetaine.
  • the formulation can contain a preservative to prevent the growth of microorganisms. Suitable preservatives include, but are not limited to, parabens, chlorobutanol, phenol, sorbic acid, and thimerosal.
  • the formulation can also contain an antioxidant to prevent degradation of the active agent(s).
  • the formulation is typically buffered to a pH of 3-8 for parenteral administration.
  • Suitable buffers include, but are not limited to, phosphate buffers, acetate buffers, and citrate buffers.
  • Water soluble polymers are often used in formulations for parenteral administration. Suitable water-soluble polymers include, but are not limited to, polyvinylpyrrolidone, dextran, carboxymethylcellulose, and polyethylene glycol.
  • Sterile injectable solutions can be prepared by incorporating the active compounds in the required amount in the appropriate solvent or dispersion medium with one or more of the excipients listed above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those listed above.
  • the compound can be incorporated into microparticles, nanoparticles, or combinations thereof.
  • the compound can be incorporated into polymeric microparticles.
  • Suitable oral dosage forms include tablets, capsules, solutions, suspensions, syrups, and lozenges. Tablets can be made using compression or molding techniques well known in the art. Gelatin or non-gelatin capsules can be prepared as hard or soft capsule shells, which can encapsulate liquid, solid, and semi-solid fill materials, using techniques well known in the art. Formulations can be prepared using a pharmaceutically acceptable carrier. As generally used herein “carrier” includes, but is not limited to, diluents, preservatives, binders, lubricants, disintegrators, swelling agents, fillers, stabilizers, and combinations thereof.
  • Suitable dosage forms for topical administration include creams, ointments, salves, sprays, gels, lotions, emulsions, and transdermal patches.
  • the formulation can be formulated for transmucosal, transepithebal, transendothelial, or transdermal administration.
  • the compounds can also be formulated for intranasal delivery, pulmonary delivery, or inhalation.
  • the compositions can further contain one or more chemical penetration enhancers, membrane permeability agents, membrane transport agents, emollients, surfactants, stabilizers, and combination thereof.
  • Suitable classes of penetration enhancers include, but are not limited to, fatty alcohols, fatty acid esters, fatty acids, fatty alcohol ethers, amino acids, phospholipids, lecithins, cholate salts, enzymes, amines and amides, complexing agents
  • liposomes, cyclodextrins, modified celluloses, and diimides liposomes, cyclodextrins, modified celluloses, and diimides
  • macrocyclics such as macrocylic lactones, ketones, and anhydrides and cyclic ureas
  • surfactants N-methyl pyrrolidones and derivatives thereof, DMSO and related compounds, ionic compounds, azone and related compounds
  • solvents such as alcohols, ketones, amides, polyols (e.g., glycols). Examples of these classes are known in the art.
  • the compounds are formulated for pulmonary delivery, such as intranasal administration or oral inhalation.
  • the respiratory tract is the structure involved in the exchange of gases between the atmosphere and the blood stream.
  • the lungs are branching structures ultimately ending with the alveoli where the exchange of gases occurs.
  • the alveolar surface area is the largest in the respiratory system and is where drug absorption occurs.
  • the alveoli are covered by a thin epithelium without cilia or a mucus blanket and secrete surfactant phospholipids.
  • Carriers for pulmonary formulations can be divided into those for dry powder formulations and for administration as solutions. Aerosols for the delivery of therapeutic agents to the respiratory tract are known in the art.
  • the formulation can be formulated into a solution, e.g., water or isotonic saline, buffered or unbuffered, or as a suspension, for intranasal administration as drops or as a spray.
  • solutions or suspensions are isotonic relative to nasal secretions and of about the same pH, ranging e.g., from about pH 4.0 to about pH 7.4 or, from pH 6.0 to pH 7.0.
  • Buffers should be physiologically compatible and include, simply by way of example, phosphate buffers.
  • a representative nasal decongestant is described as being buffered to a pH of about 6.2.
  • One skilled in the art can readily determine a suitable saline content and pH for an innocuous aqueous solution for nasal and/or upper respiratory administration.
  • the compounds described herein can be co-administered with one or more additional active agents, such as diagnostic agents, therapeutic agents, and/or prophylactic agents.
  • the linker can be prepared initially followed by covalently binding the VEGFR binding moiety (e.g. ZD-1) to the linker.
  • the detection moiety can then be linked to the linker.
  • additional VEGFR binding moieties can be added to produce the trimer (ZD-3) or tetramer (ZD-4 or ZD-5).
  • the functional-binder such as a thiol-binder
  • the functional-binder probe used in the methods disclosed herein can be synthesized by mixing a solution of compound ZD6474 and thioctic acid in a solvent followed by cooling to about 0°C.
  • a solution of EDC can be added followed by stirring at room temperature until all the reactants have been reacted.
  • a basic solution such as aqueous NH4CI can be was added to the mixture, and the aqueous solvent removed followed by addition of an organic solvent.
  • the solution can be washed and then dried to yield the crude product, which can be purified by silica gel column chromatography (5% v/v methanol/CFBCh) to get the pure product of ZD6474 probe as a yellow solid.
  • the divalent compound, ZD-2 can be prepared by adding EDC-HC1 to a solution of the compound 9 below and tBoc-N-amido-PEG2-acid in DMF cooled to 0°C. The mixture can be stirred at room temperature for 10 h. The aqueous solvent can be removed followed by addition of an organic solvent. The solution can be washed and then dried to yield the crude product, which can be purified by silica gel column chromatography to get the pure product of ZD-2 probe as a yellow solid.
  • the tetravalent compound, ZD-4 can be prepared from ZD-2 by reacting with an additional linker moiety to join two molecules of ZD-2.
  • VEGFR binding moiety and detectible moiety can be ascertained by the skilled artisan without undue experimentation.
  • the particular method will depend on the specific detectible moiety, VEGFR binding moiety, and linker.
  • the VEGFR binding moiety can be treated with a linker that can form a bond with the VEGFR binding moiety. That product can then be coupled with the detectable moiety.
  • the linker and the detectible moiety can be coupled beforehand and then coupled with the VEGFR binding moiety.
  • the linker, VEGFR binding moiety, and the detectible moiety can be coupled simultaneously.
  • the synthetic routes for preparing integrin antagonist (compound IA) and integrin antagonist dimer (compound IA dimer) as disclosed herein are disclosed in Schemes 1 and 3.
  • the integrin antagonist or integrin antagonist dimer can be coupled to the thiol-PEG spacer as described in Schemes 6 or 7.
  • the EphB4 antagonist or EphB4 antagonist dimer can be coupled to the thiol-PEG spacer as described in Schemes 8 or 9.
  • VEGFR ligands stimulate cellular responses by binding to tyrosine kinase receptors on the cell surface, known as VEGFR1 (Flt-1), VEGFR2 (Flk-1, KDR), and VEGFR3 (Flt-4).
  • VEGFR-1 and VEGFR-2 receptors are over expressed in a variety of tumors and are associated with advanced tumor growth and induction of tumor angiogenesis.
  • a tyrosine kinase signaling cascade begins in endothelial cells that stimulate the production of factors that stimulate vessel permeability, proliferation/survival, migration, and finally differentiation into mature blood vessels. This is a fundamental step in the transition of tumors from a benign state to a malignant one.
  • Erythropoietin-producing hepatocellular (Eph) Type-B receptor 4 (EphB4) is part of the largest family of membrane-bound receptor tyrosine kinases (RTK) which consists of 14 different receptors which are classed as EphA or EphB. Their ligands, the ephrins, are also cell membrane-bound, either via glycosylphosphatidylinositol (GPI)-linkage (ephrin-A ligands) or transmembrane-embedded (ephrin-B ligands).
  • GPI glycosylphosphatidylinositol
  • EphB4 demonstrates the ability to be both a tumor promoter, when over-expressed and in the absence of stimulation by its sole cognate ligand, ephrin-B2, as well as a tumor suppressor stimulated by ephrin-B2. EphB4 is overexpressed in 66% of prostate cancer clinical samples and has been implicated in prostate cancer development and progression.
  • Integrins are obligate heterodimeric cell surface receptors, which are present in all nucleated cells of the human body. Each integrin consists of one of 18 a- and one of eight b- subunits, giving rise to a repertoire of 24 different integrins in mammals. Integrins are involved in key developmental processes such as cell differentiation, cell adhesion, cell migration, cell proliferation and cell survival and are expressed in all metazoans. Each cell type exhibit a specific range of integrins and this repertoire changes according to the cellular or environmental input. In cancer, malignant cells change this repertoire in response to changes in the components or stiffness of the extracellular matrix, in response to growth factors or due to intracellular alterations such as activation of oncogenes.
  • the compounds disclosed herein bind to receptors in their target receptor expressing cells. In some embodiments, the compounds bind to receptor- (such as
  • VEGFR2 in VEGFR2 expressing cells.
  • the compounds can bind to receptors with a mean equilibrium dissociation constant (K d ) value from about 100 nM to about 0.01 nM, for e.g. about
  • nM 95 nM, about 90 nM, about 85 nM, about 80 nM, about 75 nM, about 70 nM, about 65 nM, about 60 nM, about 55 nM, about 50 nM, about 45 nM, about 40 nM, about 35 nM, about 30 nM, about 25 nM, about 20 nM, about 15 nM, about 10 nM, about 9 nM, about 8 nM, about 8 nM, about 7 nM, about 6 nM, about 5 nM, about 4 nM, about 3 nM, about 2 nM, about 1 nM, about 0.9 nM, about 0.8 nM, about 0.7 nM, about 0.6 nM, about 0.5 nM, about 0.4 nM, about 0.3 nM, about 0.2 nM, about 0.1 nM, about 0.05 nM, about 0.01 nM, or about 44.7 nM
  • the compounds disclosed can selectively inhibit the activity of receptors (such as tyrosine kinase activity of VEGFR or EphB4). In some embodiments, the compounds disclosed can selectively inhibit tyrosine kinase activity of VEGFR2.
  • the compounds disclosed can inhibit activity of receptors (such as tyrosine kinase activity of VEGFR2 or EphB4) with 50% inhibitory concentration (IC50) values of less than about 40 nM, less than about 35 nM, less than about 30 nM, less than about 25 nM, less than about 20 nM, less than about 19 nM, less than about 18 nM, less than about 17 nM, less than about 16 nM, less than about 15 nM, less than about 14 nM, less than about 13 nM, less than about 10 nM, less than about 9 nM, less than about 8 nM, less than about 7 nM, less than about 6 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM, less than about 0.9 nM, less than about 0.8 nM, less than about 0.7 nM, less than about
  • the disclosed compounds can block VEGF-stimulated endothelial cell proliferation and migration. In some embodiments, the disclosed compounds can reduce tumor vessel permeability. In some embodiments, the disclosed compounds can be used to treat late-stage (metastatic) medullary thyroid cancer, prostate cancer, or triple negative breast cancer. In some embodiments, the disclosed compounds inhibit growth of experimental lung metastasis.
  • the compounds disclosed can accumulate in selected receptor
  • the compounds can be administered via systemic administration, such as intravenous administration or subcutaneous administration, oral administration or by intratumoral injection.
  • the compounds disclosed can accumulate in selected receptor (such as VEGFR) expressing cells, for example, tumor cells, within about 36 hours, about 48 hours, about 24 hours, about 23 hours, about 22 hours, about 20 hours, about 19 hours, about 18 hours, about 17 hours, about 16 hours, about 15 hours, about 14 hours, about 13 hours, about 12 hours, about 11 hours, about 10 hours, about 9 hours, about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1.5 hours, about 1 hours, about 50 minutes, about 45 minutes, about 40 minutes, about 35 minutes, about 30 minutes, about 25 minutes, about 20 minutes, about 15 minutes, about 10 minutes, about 5 minutes post administration.
  • the selected receptor expressing cells e.g., tumor cells exhibit sufficient uptake of the compounds disclosed, post administration.
  • Sufficient refers to uptake of the disclosed compounds into selected receptor expressing cells such that optical imaging of the selected receptor expressing cells exhibit low background noise.
  • the selected receptor expressing cells exhibit uptake of greater than about 5%ID/g, greater than about 4.7%ID/g, greater than about 4.5%ID/g, greater than about 4.3%ID/g, greater than about 4%ID/g, greater than about 3.7%ID/g, greater than about 3.5%ID/g, greater than about 3.3%ID/g, greater than about 3%ID/g, greater than about 2.7%ID/g, greater than about 2.5%ID/g, greater than about 2.3%ID/g, greater than about 2%ID/g, greater than about 1.8%ID/g, greater than about 1.5%ID/g, greater than about 1.3%ID/g, greater than about l%ID/g, greater than about 0.9%ID/g, greater than about 0.8%ID/g, greater than about 0.6%ID/g, greater than about 0.5%ID/g, greater than about 0.4%ID/g, greater than about 0.3%ID/g, greater than about 0.2%ID/g, greater than about 0.1%ID/g, for example about 2. 7%ID/g, about 3.70%
  • the compounds disclosed herein can be used to image receptor expression, for example, by confocal microscopic imaging, CT imaging, PET imaging, MRI, or any combination thereof.
  • the compounds disclosed can be used to image selected receptor (such as VEGFR) expression in a disease.
  • the disclosed compounds can be used to image selected receptor (such as VEGF) stimulated endothelial cell proliferation and migration.
  • the disclosed compounds can be used to image tumor vessel permeability.
  • the disclosed compounds can be used to image late-stage (metastatic) medullary thyroid cancer.
  • the disclosed compounds can be used to image growth of experimental lung metastasis.
  • the disclosed compounds can be used to image pulmonary hypertension.
  • non-targeted cells and/or tissues such as the kidney, muscles, heart, blood, lung, gastrointestinal tract, and/or spleen exhibit low uptake of the disclosed compounds.
  • uptake of the disclosed compounds in the non-targeted tissues such as the kidney is less than about 2.5%ID/g, less than about 2.3%ID/g, less than about
  • 2%ID/g less than about 1.8%ID/g, less than about 1.5%ID/g, less than about 1.3%ID/g, less than about l%ID/g, less than about 0.9%ID/g, less than about 0.8%ID/g, less than about 0.6%ID/g, less than about 0.5%ID/g, less than about 0.4%ID/g, less than about 0.3%ID/g, less than about 0.2%ID/g, or less than about 0.
  • l%ID/g at about 24 hours, about 23 hours, about 22 hours, about 20 hours, about 19 hours, about 18 hours, about 17 hours, about 16 hours, about 15 hours, about 14 hours, about 13 hours, about 12 hours, about 11 hours, about 10, about 9 hours, about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1.5 hour, about 1 hour, about 50 minutes, about 45 minutes, about 40 minutes, about 35 minutes, about 30 minutes, about 25 minutes, about 20 minutes, about 15 minutes, about 10 minutes, about 5 minutes post administration.
  • the ratio of compound uptake in the targeted cells to non-targeted cells can be high.
  • the ratio of compound uptake in targeted cells to non-targeted cells for example, tumor cells to muscle cells can be greater than 5, greater than 6, greater than 7, greater than 8, greater than 9, greater than 10, greater than 11, greater than 12, greater than 13, greater than 14, greater than 15, greater than 16, greater than 17, greater than 18, greater than 19, greater than 20, greater than 25, greater than 30, greater than 35, greater than 40, greater than 45, or greater than 50.
  • the ratio of compound uptake in targeted cells to non-targeted cells can remain high for as long as about 2 hours, about 3 hours, about 4 hours, about 6 hours, about 10 hours, about 15 hours, about 18 hours, about 20 hours, about 24 hours, about 36 hours, about 46 hours, or as long as the compound is in a subject, post administration.
  • the compounds disclosed herein exhibit rapid clearance from the blood.
  • the liver exhibit high compound uptake at early time points of about 10 hours, about 9 hours, about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1.5 hour, about 1 hour, about 50 minutes, about 45 minutes, about 40 minutes, about 35 minutes, about 30 minutes post administration.
  • the liver uptake can be about 20%ID/g, about 18%ID/g, about 15%ID/g, about 12%ID/g, about 10%ID/g, about 8%ID/g, or about 5%ID/g.
  • the amount of compound in the liver is decreased to less than about 5%ID/g, less than about 4.7%ID/g, less than about 4.5%ID/g, less than about 4.3%ID/g, less than about
  • 0.8%ID/g less than about 0.6%ID/g, less than about 0.5%ID/g, less than about 0.4%ID/g, less than about 0.3%ID/g, less than about 0.2%ID/g, or less than about 0.1%ID/g at about 24 hours, about 23 hours, about 22 hours, about 20 hours, about 19 hours, about 18 hours, about 17 hours, about 16 hours, about 15 hours, about 14 hours, about 13 hours, about 12 hours, about 11 hours, about 10 hours post administration.
  • the disclosed compounds exhibit good extravasations and diffusion into the extracellular space. In some embodiments, the disclosed compounds can selectively bind to tumor cells, can exhibit a high diffusion rate in fluids, can exhibit fast clearance from blood, and/or exhibit good metabolic stability compared to labeled-VEGFR antibodies.
  • Methods for detecting or imaging cells expressing vascular endothelial growth factor receptor (VEGFR) in a mammal are disclosed.
  • the method can noninvasively determine VEGFR expression levels, by optical imaging, in VEGFR expressing cells.
  • the method can be used to identify patients that respond to anti- angiogenic drug.
  • the method can be used to diagnose and monitor the proliferation and development of angiogenic tumors.
  • the method comprise administering to the mammal one or more of the disclosed compound, in an amount and for a time sufficient to detect or image at least a population of the cells expressing VEGFR in the mammal to which the detectable moiety is bound.
  • the detectable moiety can be identified by confocal microscopic imaging, CT imaging, PET imaging, MRI, or any combination thereof.
  • Methods for imaging a population of cells expressing VEGFR within or about the body of an animal comprise administering to the animal an amount of one or more of the disclosed compound for a time effective to image a population of cells expressing VEGFR within or about the body of the animal.
  • the population of cells expressing VEGFR includes cancer cells, tumor cells, hyperproliferative cells, or any combination thereof.
  • the animal is a human diagnosed with cancer.
  • Methods of treating or ameliorating a symptom of a disease, dysfunction, or abnormal condition in a mammal comprise administering to the mammal one or more of the compounds disclosed herein in an amount, and for a time sufficient to treat or ameliorate the symptom of the disease, dysfunction, or abnormal condition in the mammal.
  • the compounds can contain a detectable moiety and/or therapeutic moiety that kills or inhibits an infected, dysfunctional, or abnormal cell and/or tissue directly (e.g., cisplatin) or indirectly (e.g., radioisotope or gold nanoparticle that kill or destroy cells when irradiated with a light source).
  • the method further comprises a step of taking appropriate action to “activate” or otherwise implement the activity of the moiety.
  • the detectable/therapeutic moiety attached to the disclosed compounds can be a gold nanoparticle and following administration to the patient and binding of the compound to cancer cells, the nanoparticles are irradiated, e.g., using a laser light, to kill or destroy the nearby cancer cells.
  • the method involves image guided surgery using a compound comprising a detectable moiety to detect and resect cancer from a subject followed by the use of the same or a different compound to kill the remaining cancer cells.
  • the compounds disclosed herein contain an effective amount of the one or more of the compounds disclosed.
  • the amount to be administered can be readily determined by the attending physician based on a variety of factors including, but not limited to, age of the patient, weight of the patient, disease or disorder to be imaged or treated, and presence of a pre-existing condition, and dosage form to be administered (e.g., immediate release versus modified release dosage form).
  • the effective amount is from about 0.1 mBq/kg to about 200 mBq/kg (e.g., less than about 5 mBq/kg, less than about 10 mBq/kg, less than about 15 mBq/kg, less than about 20 mBq/kg, less than about 25 mBq/kg, less than about 30 mBq/kg, less than about 40 mBq/kg, less than about 50 mBq/kg, less than about 75 mBq/kg, less than about 100 mBq/kg, less than about 125 mBq/kg, less than about 150 mBq/kg, less than about 175 mBq/kg, less than about 200 mBq/kg. Dosages greater or less than this can be administered depending on the diseases or disorder to be treated or imaged.
  • the compounds disclosed herein can be administered in an effective amount to image or treat a variety of diseases and disorders including but not limited to, proliferative disorders (e.g., cancers), diabetes, psoriasis, rheumatoid arthritis, pulmonary hypertension, Kaposi's sarcoma, hemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation, ocular diseases with retinal vessel proliferation, diabetic retinopathy, macular degeneration, and angiosarcoma.
  • proliferative disorders e.g., cancers
  • diabetes psoriasis
  • rheumatoid arthritis pulmonary hypertension
  • Kaposi's sarcoma hemangioma
  • acute and chronic nephropathies atheroma
  • arterial restenosis autoimmune diseases
  • acute inflammation ocular diseases with retinal vessel proliferation, diabetic retinopathy, macular degeneration, and angiosar
  • VEGF pathway plays a significant role in formation of new vessels which lead to increasing tumor size and metastatic spread of cancer.
  • VEGF inhibitors target this important pathway in cancer progression.
  • immunotherapy has emerged one the most effective treatment changing paradigm in cancer.
  • VEGF receptor PET imaging has a role in determining how immunotherapy is clinically used. Studies have shown that the efficacy of immunotherapy in the treatment of lung cancer is dependent on tumor vascularity which in turn can be measured by VEGF receptor expression. Measuring the uptake of VEGF using the compounds disclosed herein (such as 18F-
  • ZD-2) could be used to screen patients with lung cancer to determine which ones would have a greater chance of responding to immunotherapy beyond traditional genetic markers, such a PD- Ll.
  • Figure 7 shows therapy data generated for 177 Lu-DiZD (divalent compound) compared with anti-PDl on triple native breast cancer model.
  • the disclosed compounds are particularly advantageous in treating and/or imaging the growth of primary and recurrent solid tumors.
  • Exemplary cancers which can be treated and/or imaged include, but are not limited to, cancer of the skin, colon, uterine, ovarian, pancreatic, lung, bladder, breast, renal system, and prostate.
  • cancers include, but are not limited to, cancers of the brain, liver, stomach, esophagus, head and neck, testicles, cervix, lymphatic system, larynx, esophagus, parotid, biliary tract, rectum, endometrium, kidney, and thyroid; including squamous cell carcinomas, adenocarcinomas, small cell carcinomas, gliomas, neuroblastomas, and the like.
  • the compounds are expected to inhibit the growth of those primary and recurrent solid tumors which are associated with different receptors such as VEGF, EphB4, or integrin, especially those tumors which are significantly dependent on receptors for their growth and spread, including for example, certain tumors of the colon, breast, prostate, lung, vulva and skin.
  • the compounds described herein can also be used to treat or image metastatic cancer.
  • the compounds can be used in patients who have received prior chemo, radio, or biological therapy or in previously untreated patients. In one embodiment, the patient has received previous chemotherapy.
  • the compounds can be administered using a variety of routes including systemic administration, such as intravenous administration or subcutaneous administration, oral administration or by intratumoral injection.
  • systemic administration such as intravenous administration or subcutaneous administration, oral administration or by intratumoral injection.
  • the compounds disclosed can also be used for imaging in patients who have been rendered free of clinical disease by surgery, chemotherapy, and/or radiotherapy.
  • the disclosed compounds are also particularly advantageous in treating and/or imaging pulmonary hypertension such as Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and PH associated with interstitial lung disease (WHO group III).
  • CTEPH Chronic Thromboembolic Pulmonary Hypertension
  • WHO group III PH associated with interstitial lung disease
  • the standard test used to diagnose CTEPH is a pulmonary angiogram, usually performed at the time of right heart catheterization.
  • a ventilation-perfusion (V/Q) lung scanning is generally used in distinguishing chronic thromboembolic pulmonary hypertension from other non-embolic causes of PHT PET imaging can replace the V/Q scan.
  • the disclosed compounds are also particularly advantageous in transplantation procedures. Although transplantation science continues to improve short term outcomes and survival of transplant patients, long term outcomes are plagued by different forms of chronic rejection in all organ transplantation including heart, lung and kidney. A sign of chronic rejection is neovascularization, which is mediated by VEGF pathway. Currently, invasive testing from heart catheterization to invasive biopsies are needed to confirm these diagnoses depending on the organ involved. VEGFR imaging can lead to earlier detection of chronic rejection via PET imaging with the compounds disclosed herein, such as 18F-ZD-2.
  • the disclosed compounds are also particularly advantageous in vascular applications. Additional uses in cardiovascular patient care include vascular imaging of aortic aneurysms and vascular access graft imaging to assess for disease progression.
  • atomic force microscopy As described herein, atomic force microscopy (AFM), by the virtue of its spatial resolution and its ability to function in aqueous systems, is a powerful tool to probe biological systems in their native state at a nanoscale resolution. Disclosed herein are methods based on
  • FIG. 8 is a flow diagram showing method of using AFM to design conforming compounds based on spatial information of cell-surface receptors.
  • drug compounds such as ZD6474 (vandetanib or ZD-1)
  • VEGFR vascular endothelial growth factor receptors
  • HAVECs live human umbilical vein endothelial cells
  • exemplary receptors in which the spatial information can be determined include PD-L1, EphB4 in cancer cells, PD1 CTLA4 in T cells, integrin, angiotensin-converting enzyme (ACE) (such as in SARS-Cov-2 infection), estrogen receptor (ER), or a combination thereof.
  • ACE angiotensin-converting enzyme
  • ER estrogen receptor
  • the interaction of the integrin antagonists compounds IA and IA dimer in Schemes 2 and 4
  • ROVECs live human umbilical vein endothelial cells
  • Ephb4 antagonists compounds EphB4-007 monomer and EphB4 dimer in Schemes 8 and 9
  • EphB4 receptors in MDA- MB-468 human triple negative breast cancer cells were used in determining the spatial information of EphB4.
  • the method for determining the spatial distribution of receptors on a cell can include functionalizing an AFM tip with one or more receptor binding moieties to form a functionalized AFM tip; contacting the functionalized AFM tip with the cell to facilitate binding of the one or more receptor binding moieties with the receptors and form a binder-receptor complex; determining the number of each receptor distributed in an area of the AFM tip, and deriving a maximum distance between two neighboring receptors.
  • the receptors on the cell surface can be the same or different.
  • the methods can be used to determine the spatial distribution of different receptors on a cell for the design of bifunctional multivalent ligands that target different receptors at one time.
  • the methods can be used to determine the spatial distribution of the same or different receptors selected from VEGFR, PD- Ll, EphB4 (such as in cancer cells), PD1 CTLA4 (such as in T cells), integrin, angiotensin converting enzyme (ACE) (such as in SARS-Cov-2 infection), estrogen receptor (ER), or a combination thereof.
  • EphB4 such as in cancer cells
  • PD1 CTLA4 such as in T cells
  • integrin such as in T cells
  • integrin angiotensin converting enzyme (ACE) (such as in SARS-Cov-2 infection)
  • ER estrogen receptor
  • the methods can be used to determine the spatial distribution of EphB4 and EphA4.
  • the receptor binding moiety can be a monomer or a dimer and may be selected from a small molecule therapeutic agent, a peptide, an antibody, an antibody fragment, a carbohydrate, an siRNA, a protein, a nucleic acid, an aptamer, a nanoparticle, a cytokine, a chemokine, a lymphokine, a lipid, a lectin, or a combination thereof.
  • the method for determining the spatial distribution of receptors on a cell can include conjugating a receptor binding moiety to a functional moiety to form a functional- binder conjugate.
  • the method for determining the spatial distribution of VEGFR, integrin, or EphB4 in a cell can include conjugating a VEGFR binding moiety, an integrin binding moiety, or an EphB4 binding moiety, respectively, to a functional moiety to form a functional-binder conjugate.
  • the functional moiety can be chosen based on the nature of the AFM tips. For example, when the tip is silicon, the functional moiety can include a thiol group.
  • the AFM silicon tip can be coated with various metals, such as Au, Pt, Cr, and Ni to impart electrical conductivity or even magnetic conductivity.
  • a metal-affinity ligand can be conjugated to the binder and subsequently used to functionalize the AFM tip. Methods of conjugating the binding moiety to a thiol moiety to form the thiol-binder conjugate are described herein.
  • the method for determining the spatial distribution of receptors on a cell can further comprise functionalizing the AFM tip with the functional-binder conjugate (100% solution) or a diluted solution of the functional-binder conjugate to form a functionalized AFM tip.
  • the method for determining the spatial distribution of VEGFR in a cell can further include functionalizing an AFM tip with the functional-binder (e.g., thiol-binder) conjugate or a diluted solution of the functional-binder conjugate to form a functionalized AFM tip.
  • the diluted solution of the functional-binder conjugate can comprise up to 95% by weight polyethylene glycol functionalized with a functional group (e.g., thiol group).
  • the diluted solution of the functional-binder conjugate can comprise 3% or greater, 5% or greater, 10% or greater, 15% or greater, or 25% or greater by weight functional-binder conjugate and 97% or less, 95% or less, 90% or less, 85% or less, or 75% or less by weight polyethylene glycol functionalized with a functional group.
  • AFM tips can be functionalized with the thiol-binder conjugate by first rinsing and then drying AFM tips prior to use. The tips can then be immersed overnight in an aqueous solution containing the thiol-binder conjugate diluted with various ratios of thiol PEG functionalized with thiol. The functionalized AFM tips can be rinsed with water and then used immediately in the following steps.
  • the functionalized AFM tip can then be contacted with the cell to bind the functional -binder conjugate to the receptor (such as VEGFR, integrin, EphB4, or EphA4) present on the cell and form a binder-receptor complex.
  • the cell can be cultured with the functional-binder conjugate or the diluted solution of functional-binder conjugate until the cell reaches 50% or greater confluence.
  • Adhesive force measurements can be used to determine a dissociative force (force required to dissociate) of an ensemble of the binder-receptor (such as binder-VEGFR) complex and of a single binder-receptor complex.
  • AFM adhesive force measurements can be conducted at room temperature and in the native environment of live cells (such as live HUVECs or MDA-
  • the method can include scanning a surface of the cell using the adhesive force measurement mode, mapping the adhesive force of the binder- receptor complex, selecting a region of the cell with the highest adhesive force signal, deriving a histogram of the dissociative forces obtained from statistics of the adhesive force over the region, and analyzing the histograms and differentiate individual force peaks to determine the dissociative force of the ensemble of the binder-receptor complex and a single binder-receptor complex.
  • the spring constant, kc (which is proportional to the tip-sample interaction force) of each individual compound can be calibrated in solution using the software, the thermal fluctuation method.
  • modified tips prepared as described can be used to probe the ZD6474/VEGFR specific binding events at the retraction velocity of 1200 nm/s.
  • modified tips prepared as described can be used to probe the peptide/EphB4 specific binding events.
  • the loading rates were then calculated by multiplying the retraction velocity (nm/s) by the effective spring constant of the cantilever (nN/nm), which in the example below, resulted in a value of loading rate ranging from 60-66 nN/s.
  • the method can further include determining the number of receptors (such as VEGFR) distributed in an area of the AFM tip.
  • the number of receptors can be determined by dividing the dissociative force of the ensemble of the binder-receptor complex by the dissociative force of the single binder-receptor complex. In the example below, the number of VEGFR within the detection area was estimated around 16 and the detection area of the AFM tip was estimated to be about 250 nm 2 .
  • a maximum distance between two neighboring VEGFR can be derived using a maximizing minimum algorithm.
  • the maximal distance of proximal VEGFR can be transformed into a pure mathematical problem that optimizes the random location of the given N points by maximizing their inter-point distances. Specifically, by maximizing the total distance the function: subject to j
  • the receptors can be the same or different.
  • the methods can utilize information obtained from the AFM methods that provide the proximal receptor distance between two or more receptors on the cell surface. Once the spatial distribution of the receptors are obtained, multivalent compounds can be synthesized having two or more binding moieties.
  • the multivalent compounds can comprise a first moiety and a second moiety covalently linked by a first linker, Li, wherein the first moiety comprises one or more receptor binding moieties, and the second moiety comprises an additional one or more receptor binding moieties.
  • the first linker can have a length not substantially less than, equal to, or greater than the proximal receptor distance.
  • substantially refers to the complete or nearly complete extent or degree of an action, characteristic, property, state, structure, item, or result.
  • the first linker can have a length not substantially less than the proximal receptor distance would mean that the first linker has a length within 10%, preferably within 8%, more preferably within 5% of the proximal receptor distance. In some examples, the first linker can have a length within 20%, preferably within 15%, more preferably within 10%, of the proximal receptor distance. Preferably, the first linker has a length within 5% of the proximal receptor distance.
  • the multivalent compounds can have a binding affinity to the receptor that is greater than 10 times, greater than 100 times, greater than 1,000 times, or greater than 2,000 times the binding affinity of a single-valent compound alone. Depending on the nature of the receptors, the first moiety and the second moiety can be the same or different.
  • Atomic force microscopy by the virtue of its spatial resolution and its ability to function in aqueous systems, has emerged as a powerful tool to probe biological systems in their native state at a nanoscale resolution.
  • AFM Atomic force microscopy
  • ZD6474 vandetanib
  • VEGFR vascular endothelial growth factor receptors
  • the molecular probe ZD6474 was first conjugated with thioctic acid (Figure 2A) and then attached to a gold-coated AFM tip by means of a strong Au-S bond ( Figure 2B).
  • the ligand-functionalized tip was brought into contact with the surface of the HUVECs where the binding of ZD6474/VEGFR took place.
  • the tip was then withdrawn from the surface, pulling ligand out of the binding pocket.
  • the force required to separate the ligand from its specific binding site, the “ligand dissociation force” was determined.
  • thiol modified polyethylene glycol (Thiol PEG) was used as a competing molecule to reduce the number of ZD6474 probe attached to the AFM tip, which could reduce the number of binding events even at a molecular level during each contact by changing the ratio between the ZD6474 probe and the thiol PEG.
  • the contact area of the AFM tip restricted the number of receptors accessed in the force measurements, and the number of receptors within the detecting area ( NVEGFR ) could be readily calculated from the AFM force measurement as
  • NvEGFR F ensemble! F ingle , where F ensemble was the ensemble of multiple dissociation forces obtained by the 100%-tip, and F single was the dissociation force of ZD6474/VEGFR at a single-molecule level that was obtained by the 5%-tip.
  • the value of Fensembie was 728 ⁇ 16 pN and F single was 45 ⁇ 1 pN, and consequently NVEGFR was calculated to be 16 within the effective contact area of the AFM tip measuring about 250 nm 2 .
  • the maximal distance between the two adjacent VEGFR on cell periphery in live HUVECs was determined as about 48 A. This is believed to be the first report of receptor distance in live cells measured by AFM.
  • Figure 4 presented a series of multivalent ligands that were used in this example of hybrid multivalent binding. All these compounds were prepared and characterized accordingly (see Yang et ak, Single-Molecule Force Measurement Guides the Design of Multivalent Ligands with Picomolar Affinity, Angew.Chem. Int. Ed.
  • a linker with length of ⁇ 14 A that was greatly shorter than the proximal VEGFR distance in HUVECs was used to tether ZD6474 entities and construct a bivalent ZD-2, in which the statistical effect was believed to be dominated in the binding.
  • a second bivalent ZD-3 with linker of ⁇ 47 A that corresponded to the estimated distance of neighboring VEGFR was also constructed to assess the chelate effect.
  • the IC50 of the monovalent ZD-1 was determined to be 47 ⁇ 3.0 nM, whereas I (jo of the bivalent designs ZD-2 and ZD-3 were found to be 1.8 ⁇ 0.2 nM and 2.2 ⁇ 0.2 nM, respectively.
  • ZD-2 and ZD-3 thus represented an approximate 20-fold improvement in the affinity compared to that of ZD-1. It suggests the distinction of statistical and chelate effects in the bivalent binding by using the right lengths of linkers, and both statistical and chelate effects lead to increased receptor binding.
  • the hybrid tetravalent ZD-4 was constructed to effectively combine the statistical and chelate effect in one structure for further optimization of binding affinity.
  • ZD-4 showed unprecedentedly increased binding affinity with measured /C50 as low as 0.025 ⁇ 0.002 nM, which presents almost 2000-fold improvement over
  • IC50 was revealed 0.89 ⁇ 0.08 nM, which showed a 2-fold increase compared to the bivalent ligands and 35-fold less potent than the hybrid ZD-4.
  • the comparison of ZD-4 with ZD-5 supports the position that optimized multivalent binding can be achieved by hybrid multivalent design.
  • the improved binding affinity of ZD-4 to VEGFR was investigated using in vivo VEGFR-targeting positron emission tomography (PET) imaging of U87 glioblastoma- bearing mice. Increased tumor uptake of the imaging tracer will be associated with improved VEGFR targeting (Folkman, J New England J. Med. 1971, 285, 1182-1186; and Ferrara, N. et ak, Nat. Med. 2003, 9, 669-676).
  • PET radiotracer 64 Cu-ZD4 shown below
  • specific activity of 0.3-0.5 MBq/nmol was compared with its parent drug ZD6474 derived radiotracer 64 Cu-ZD6474 for their tumor uptake.
  • Representative whole-body 3D images at 24 h post injection (p.i.) are shown in Figure 6A.
  • High tumor uptake of 64 CU-ZD4 was observed as indicated by the arrow, and revealed 64 Cu-ZD4 to be a suitable PET probe for in vivo tumor VEGFR imaging.
  • the tumor uptake of 64 Cu-ZD6474 was revealed by the PET imaging to be much less.
  • ROIs regions of interest quantification analysis of tumor uptake was performed to obtain an imaging ROI-derived percentage of the injected radioactive dose per gram of tissue (%ID/g).
  • the tumor uptake of 64 Cu-ZD4 probe was 6.16 ⁇ 0.30 %ID/g as early as 2 h p.i., and increased to 7.24 ⁇ 0.23 %ID/g and 7.90 ⁇ 0.39 %ID/g at 6 h and 24 h p.i., respectively.
  • the tumor uptake of 64 Cu-ZD6474 was only 0.30 ⁇ 0.11 %ID/g at 2 h, 0.66 ⁇ 0.04 %ID/g at 6 h, and 0.46 ⁇ 0.14 %ID/g at 24 h p.i..
  • the following histological study confirmed the abundant expression of VEGFR in the U87 tumor, which accounted for the high uptake of VEGFR-specific radiotracers.
  • the in vivo PET imaging clearly showed that the improved binding of hybrid ZD-4 led to a significantly increased tumor uptake of 64 Cu-ZD4, which was 12-times higher than that of radiolabeled parent monomer 64 Cu- ZD6474 ( P ⁇ 0.0001).
  • the high tumor uptake and favorable pharmacological properties suggest 64 CU-ZD4 a suitable PET radiopharmaceutical. Promising radionuclide-based therapeutic products could be produced by incorporation into developed agents with appropriate radionuclides.
  • VEGF targeted imaging can be useful in other groups of pulmonary hypertension such as Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and PH associated with interstitial lung disease (WHO group III).
  • CTEPH Chronic Thromboembolic Pulmonary Hypertension
  • WHO group III PH associated with interstitial lung disease
  • the standard test used to diagnose CTEPH is a pulmonary angiogram, usually performed at the time of right heart catheterization.
  • V/Q scan is used to screen patients. PET imaging can replace V/Q scan.
  • VEGF pathway plays a significant role in formation of new vessels which lead to increasing tumor size and metastatic spread of cancer.
  • VEGF inhibitors (8 FDA approved drugs) target this important pathway in cancer progression.
  • Immunotherapy has emerged one the most effective treatment changing paradigm in cancer.
  • VEGF receptor PET imaging has a role in determining how immunotherapy is clinically used.
  • Studies have shown that the efficacy of immunotherapy in the treatment of lung cancer is dependent on tumor vascularity which in turn can be measured by VEGF receptor expression.
  • Measuring the uptake of VEGF using 18F-ZD- G2 could be used to screen patients with lung cancer to determine which ones would have a greater chance of responding to immunotherapy beyond traditional genetic markers, such a PD- Ll.
  • Figure 7 shows therapy data generated of 177 Lu-DiZD compared with anti-PDl on triple native breast cancer model.
  • Transplantation Although transplantation science continues to improve short term outcomes and survival of transplant patients, long term outcomes are plagued by different forms of chronic rejection in all organ transplantation including heart, lung and kidney. Hallmark of chronic rejection is neovascularization, which is mediated by VEGF pathway. Currently, invasive testing from heart catheterization to invasive biopsies are needed to confirm these diagnoses depending on the organ involved. We believe VEGFr2 imaging can lead earlier detection of chronic rejection via PET imaging with 18F-ZD-G2, like PAH.
  • Vascular Applications Additional uses in cardiovascular patient care include vascular imaging of aortic aneurysms and vascular access graft imaging to assess for disease progression.
  • Figure 8 is a flow diagram showing method of using AFM to design conforming compounds.
  • Drug Candidates a) Peptide targeting ephrin type-B receptor 4, which makes up the largest subgroup of the receptor tyrosine kinase family and emerges as critical regulators postnatal angiogenic remodeling and tumor neovascularization. b) Synthetic antagonist for integrin, which is another transmembrane receptor and activate signal transduction pathways that mediate cellular signals such as regulation of the cell cycle, organization of the intracellular cytoskeleton, and movement of new receptors to the cell membrane.
  • HUVEC cells that express abundant integrin receptors for integrin-towards ligand-to- receptor force mapping were cultured.
  • MDA-MB-468 human triple negative breast cancer cells that express abundant ephb4 receptor for ephb4-to wards ligand-to-receptor force mapping were cultured.
  • Schemes 1 and 2 show synthetic procedure of compound IA and its structure, respectively.
  • Scheme 4 A chemical structure Scheme 5 shows PEG linker being covalently conjugated with thiol (SH) functional group, for attachment of the functional ligands to the gold-made AFM tips.
  • SH thiol
  • Scheme 6 details synthesis of SH-PEG-IA monomer which 5% and 100% functionalized AFM tips were prepared, and the cells were cultured.
  • Scheme 7 details synthesis of SH-PEG tagged IA dimer.
  • Scheme 8 details synthesis of SH-PEG tagged ephb4 monomer.
  • Scheme 9 details synthesis of SH-PEG tagged ephb4 dimer.
  • Scheme 9 Prepare SH-PEG tagged ephb4 dimer for AFM tip functionalization.
  • Figures 9 and 10 show AFM height and force mapping of HUVEC cells using 100% IA monomer functionalized AFM tip ( Figure 9) and of MDA-MB-468 cells using 100% ephb4 monomer functionalized AFM tip ( Figure 10).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés de sondage de la distribution et de la distance des récepteurs de surface cellulaire et l'utilisation de ceux-ci pour fabriquer des ligands multivalents ciblant lesdits récepteurs. L'invention concerne également des procédés de fabrication des ligands multivalents et de détection ou d'imagerie de cellules exprimant des récepteurs à l'aide des composés.
PCT/US2021/015713 2020-01-29 2021-01-29 Ligands multivalents ciblant des récepteurs de surface cellulaire et plateforme de mesure de force pour leur fabrication Ceased WO2021155151A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062967329P 2020-01-29 2020-01-29
US62/967,329 2020-01-29

Publications (1)

Publication Number Publication Date
WO2021155151A1 true WO2021155151A1 (fr) 2021-08-05

Family

ID=77079622

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/015713 Ceased WO2021155151A1 (fr) 2020-01-29 2021-01-29 Ligands multivalents ciblant des récepteurs de surface cellulaire et plateforme de mesure de force pour leur fabrication

Country Status (1)

Country Link
WO (1) WO2021155151A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024025991A1 (fr) * 2022-07-27 2024-02-01 The Methodist Hospital System Méthodes de diagnostic et de traitement de l'hypertension pulmonaire

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014071074A2 (fr) * 2012-11-01 2014-05-08 Abbvie Inc. Immunoglobulines à domaine variable double anti-vegf/dll4 et leurs utilisations
US20150284416A1 (en) * 2015-06-16 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Novel linkers for conjugation of cell-binding molecules
US20170073328A1 (en) * 2014-05-15 2017-03-16 The Methodist Hospital System Multivalent ligands targeting vegfr
US20170247475A1 (en) * 2011-04-01 2017-08-31 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to vegf and ang2
WO2017165464A1 (fr) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Molécules multispécifiques et multifonctionnelles et leurs utilisations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170247475A1 (en) * 2011-04-01 2017-08-31 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to vegf and ang2
WO2014071074A2 (fr) * 2012-11-01 2014-05-08 Abbvie Inc. Immunoglobulines à domaine variable double anti-vegf/dll4 et leurs utilisations
US20170073328A1 (en) * 2014-05-15 2017-03-16 The Methodist Hospital System Multivalent ligands targeting vegfr
US20150284416A1 (en) * 2015-06-16 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Novel linkers for conjugation of cell-binding molecules
WO2017165464A1 (fr) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Molécules multispécifiques et multifonctionnelles et leurs utilisations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024025991A1 (fr) * 2022-07-27 2024-02-01 The Methodist Hospital System Méthodes de diagnostic et de traitement de l'hypertension pulmonaire

Similar Documents

Publication Publication Date Title
US11020493B2 (en) Double-labeled probe for molecular imaging and use thereof
Li et al. Self-assembled NIR-II fluorophores with ultralong blood circulation for cancer imaging and image-guided surgery
US8323621B2 (en) Multi-use multimodal imaging chelates
Shi et al. PET/NIR-II fluorescence imaging and image-guided surgery of glioblastoma using a folate receptor α-targeted dual-modal nanoprobe
US10011587B2 (en) Multivalent ligands targeting VEGFR
Zhang et al. In vivo irreversible albumin-binding near-infrared dye conjugate as a naked-eye and fluorescence dual-mode imaging agent for lymph node tumor metastasis diagnosis
EP3510399B1 (fr) Colorants nir ciblés sur psma et leurs utilisations
Qian et al. Mitochondria-targeted delocalized lipophilic cation complexed with human serum albumin for tumor cell imaging and treatment
Sun et al. Bifunctional supramolecular prodrug vesicles constructed from a camptothecin derivative with a water-soluble pillar [5] arene for cancer diagnosis and therapy
KR20170029430A (ko) Ph 반응성 중합체의 라이브러리 및 이의 나노프로브
Ye et al. A New γ-Glutamyltranspeptidase-Based Intracellular Self-Assembly of Fluorine-18 Labeled Probe for Enhancing PET Imaging in Tumors
JP2017503004A (ja) 近赤外蛍光造影バイオイメージング剤及びその使用方法
CN102196823A (zh) 纤维化疾病的成像剂
Yuzhakova et al. In vivo multimodal tumor imaging and photodynamic therapy with novel theranostic agents based on the porphyrazine framework-chelated gadolinium (III) cation
Yang et al. A df heteronuclear complex for dual-mode phosphorescence and magnetic resonance imaging
JP2018513160A (ja) テキサフィリン−リン脂質複合体及びその調製方法
US10822355B2 (en) Ultralow-power near infrared lamp light operable targeted organic nanoparticle photodynamic therapy
CN113248408B (zh) 一种多模态分子影像探针P-FFGd-TCO及其制备方法与应用
Li et al. Zirconium-containing nanoscale coordination polymers for positron emission tomography and fluorescence-guided cargo delivery to triple-negative breast tumors
Yu et al. Sequential diagnosis and treatment for colon cancer via derived iridium and indocyanine green hybrid nanomicelles
Zhu et al. Charge-conversional polyethylenimine-entrapped gold nanoparticles with 131 I-labeling for enhanced dual mode SPECT/CT imaging and radiotherapy of tumors
Shen et al. Alkyl chain length-regulated in situ intelligent nano-assemblies with AIE-active photosensitizers for photodynamic cancer therapy
WO2021155151A1 (fr) Ligands multivalents ciblant des récepteurs de surface cellulaire et plateforme de mesure de force pour leur fabrication
JPWO2010101298A1 (ja) 蛍光ｍｒｉプローブ
Yang et al. Mannose functionalized small molecule nanodrug self-assembled from amphiphilic prodrug connected by disulfide bonds for synergistic cancer chemotherapy and photodynamic/photothermal therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21747693

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21747693

Country of ref document: EP

Kind code of ref document: A1